U.S. patent application number 16/070044 was filed with the patent office on 2019-01-17 for vascular extracellular matrix hydrogel.
The applicant listed for this patent is University of Pittsburgh - Of the Commonwealth System of Higher Education. Invention is credited to Stephen F. Badylak, George R. Fercana, JR., Thomas G. Gleason, Julie Anne Phillippi.
Application Number | 20190015552 16/070044 |
Document ID | / |
Family ID | 59311652 |
Filed Date | 2019-01-17 |
![](/patent/app/20190015552/US20190015552A1-20190117-D00000.png)
![](/patent/app/20190015552/US20190015552A1-20190117-D00001.png)
![](/patent/app/20190015552/US20190015552A1-20190117-D00002.png)
![](/patent/app/20190015552/US20190015552A1-20190117-D00003.png)
![](/patent/app/20190015552/US20190015552A1-20190117-D00004.png)
![](/patent/app/20190015552/US20190015552A1-20190117-D00005.png)
![](/patent/app/20190015552/US20190015552A1-20190117-D00006.png)
![](/patent/app/20190015552/US20190015552A1-20190117-D00007.png)
![](/patent/app/20190015552/US20190015552A1-20190117-D00008.png)
![](/patent/app/20190015552/US20190015552A1-20190117-D00009.png)
![](/patent/app/20190015552/US20190015552A1-20190117-D00010.png)
View All Diagrams
United States Patent
Application |
20190015552 |
Kind Code |
A1 |
Badylak; Stephen F. ; et
al. |
January 17, 2019 |
Vascular Extracellular Matrix Hydrogel
Abstract
Provided herein are methods of making an ECM gel from vascular
tissue. Also provided herein are ECM compositions prepared from
vascular tissue, and methods of use of those compositions, for
example in treatment of aneurysms, and for vascularization or
re-vascularization.
Inventors: |
Badylak; Stephen F.; (West
Lafayette, IN) ; Fercana, JR.; George R.;
(Pittsburgh, PA) ; Gleason; Thomas G.;
(Pittsburgh, PA) ; Phillippi; Julie Anne;
(Pittsburgh, PA) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
University of Pittsburgh - Of the Commonwealth System of Higher
Education |
Pittsburgh |
PA |
US |
|
|
Family ID: |
59311652 |
Appl. No.: |
16/070044 |
Filed: |
January 13, 2017 |
PCT Filed: |
January 13, 2017 |
PCT NO: |
PCT/US2017/013355 |
371 Date: |
July 13, 2018 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
62278065 |
Jan 13, 2016 |
|
|
|
Current U.S.
Class: |
1/1 |
Current CPC
Class: |
A61L 2430/20 20130101;
A61K 35/12 20130101; A61L 27/507 20130101; A61L 27/52 20130101;
C07K 14/75 20130101; C07K 14/745 20130101; A61P 35/00 20180101;
A61L 27/3625 20130101; A61L 27/225 20130101; A61L 27/3633 20130101;
A61L 27/3691 20130101; A61L 27/3687 20130101 |
International
Class: |
A61L 27/36 20060101
A61L027/36; A61L 27/22 20060101 A61L027/22; A61L 27/50 20060101
A61L027/50 |
Goverment Interests
STATEMENT REGARDING FEDERAL FUNDING
[0005] This invention was made with government support under Grant
Nos. HL127214 and HL109132 awarded by the National Institutes of
Health. The government has certain rights in the invention.
Claims
1. A method of preparing an extracellular matrix (ECM) material,
comprising: a. incubating vascular adventitial tissue in a
zwitterionic detergent; b. incubating the tissue in Trypsin-EDTA;
c. incubating the tissue with an anionic detergent; d. disinfecting
the tissue, optionally with peracetic acid, producing a
decellularized ECM material; e. lyophilizing the decellularized ECM
material; f. comminuting the decellularized ECM material; g.
partially or completely solubilizing the decellularized ECM
material with an acid protease to produce solubilized ECM; and h.
neutralizing the solubilized ECM to produce an ECM pre-gel.
2. The method of claim 1, wherein the decellularized ECM material
is not completely digested with the acid protease, producing an ECM
pre-gel that is able to gel at 37.degree. C. comprising undigested
decellularized ECM particles.
3. The method of claim 1, wherein the ECM material is prepared
without a dialysis step or a crosslinking step.
4. The method of claim 1, wherein: a. the zwitterionic detergent is
CHAPS; b. the anionic detergent is SDS; c. the acid protease is
pepsin; or d. the decellularized ECM material is solubilized with
an acid protease in a solution having a pH of from 1 to 4, from 1
to 2, or 2.0.+-.0.3.
5. The method of claim 1, comprising dispersing the ECM material in
a natural or a synthetic polymer composition, optionally wherein
the natural or a synthetic polymer composition is one or more of: a
second ECM material, fibrin, collagen, polyester (PE), polyurethane
(PU), poly(ester urethane) urea (PEUU), poly(ether ester urethane)
urea (PEEUU), poly(ester carbonate urethane)urea PECUU),
poly(carbonate urethane)urea (PCUU) copolymer, polyolefin
(polyalkene), polycarbonate, polyanhydride, polyether, polyurea,
polyurethane, polyketone, and fluoropolymer.
6. The method of claim 5, wherein the ECM material is mixed with
the natural or synthetic polymer composition prior to or during
gelation of the ECM material.
7. The method of claim 5, wherein the pre-gel is mixed with fibrin
and fibrinogen and is gelled while the fibrin is cross-linked with
the fibrinogen.
8. An ECM composition comprising devitalized,
acid-protease-digested aortic adventitial tissue, having a pH of
from 6.8 to 7.8.
9. The composition of claim 8, wherein the devitalized,
acid-protease-digested aortic adventitial tissue is not dialyzed or
chemically crosslinked.
10. A method of treating an aneurysm in a patient, comprising
administering to a surface of a blood vessel having an aneurysm, a
devitalized, acid-protease-digested vascular adventitial tissue, as
claimed in claim 8, wherein the vascular adventitial tissue is
optionally aortic adventitial tissue, optionally, wherein the blood
vessel is the aorta of the patient.
11. The method of claim 10, wherein the devitalized,
acid-protease-digested vascular adventitial tissue is prepared by:
a. incubating vascular adventitial tissue, such as aortic
adventitial tissue, in a zwitterionic detergent, wherein the
vascular adventitial tissue is optionally bovine, ovine, or
porcine; b. incubating the tissue in Trypsin-EDTA; c. incubating
the tissue with an anionic detergent; d. disinfecting the tissue,
optionally with peracetic acid, producing a decellularized ECM
material; e. lyophilizing the decellularized ECM material; f.
comminuting the decellularized ECM material; g. partially or
completely solubilizing the decellularized ECM material with an
acid protease to produce solubilized ECM; h. neutralizing the
solubilized ECM to produce an ECM pre-gel, and i. optionally,
gelling the ECM pre-gel at a temperature at which the ECM pre-gel
gels to produce an ECM gel.
12. A method of vascularizing or re-vascularizing living tissue in
a patient, comprising administering to a surface of a tissue ex
vivo, or in vivo, a devitalized, acid-protease-digested vascular
adventitial tissue, as claimed in claim 8, wherein the vascular
adventitial tissue is optionally aortic adventitial tissue.
13. The method of claim 12, wherein the tissue is a living blood
vessel.
14. The method of claim 12, wherein: a. the tissue is a wound of a
patient, optionally a skin wound, a diabetic ulcer, or a diabetic
foot ulcer, and the devitalized, acid-protease-digested vascular
adventitial tissue is administered to the wound; b. wherein the
tissue is living bone tissue of a patient, optionally a damaged
bone, or bone exhibiting osteoporosis, and the devitalized,
acid-protease-digested vascular adventitial tissue is administered
to the bone; or c. wherein the tissue is myocardium and/or
vasculature thereof in a patient, optionally a wound in a patient's
myocardium or an infarct, and the devitalized,
acid-protease-digested vascular adventitial tissue is administered
to the patient's myocardium, and optionally to the wound or infarct
in the patient's myocardium.
15. The method of claim 12, wherein the devitalized,
acid-protease-digested vascular adventitial tissue is prepared by:
a. incubating vascular adventitial tissue, such as aortic
adventitial tissue, in a zwitterionic detergent, wherein the
vascular adventitial tissue is optionally bovine, ovine, or
porcine; b. incubating the tissue in Trypsin-EDTA; c. incubating
the tissue with an anionic detergent; d. disinfecting the tissue,
optionally with peracetic acid, producing a decellularized ECM
material; e. lyophilizing the decellularized ECM material; f.
comminuting the decellularized ECM material; g. partially or
completely solubilizing the decellularized ECM material with an
acid protease to produce solubilized ECM; h. neutralizing the
solubilized ECM to produce an ECM pre-gel, and i. optionally,
gelling the ECM pre-gel at a temperature at which the ECM pre-gel
gels to produce an ECM gel.
16. The method of claim 1, wherein the vascular adventitial tissue
is bovine, ovine, or porcine.
17. The method of claim 1, wherein the adventitial tissue is aortic
adventitia.
18. The method of claim 1, further comprising, gelling the ECM
pre-gel at a temperature at which the ECM pre-gel gels to produce
an ECM gel.
19. The composition of claim 8, wherein the composition is a gel,
and, as compared to acid-protease-digested porcine small intestine
submucosa, the gel comprises longer fibers and at least 50% lower
FGF-1 or FGF-2 content, and optionally has increased HB-EGF
(Heparin Binding EGF Like Growth Factor) content and/or lower
content of one or more of Angiopoietin 2; Endostatin; IGFBP1
(Insulin Like Growth Factor Binding Protein 1); PTX3 (Pentraxin 3);
Prolactin; Serpin B5; or TIMP4 (TIMP Metallopeptidase Inhibitor 4),
or optionally has increased HB-EGF (Heparin Binding EGF Like Growth
Factor) content, and lower content of Angiopoietin 2; Endostatin;
IGFBP1 (Insulin Like Growth Factor Binding Protein 1); PTX3
(Pentraxin 3); Prolactin; Serpin B5; and TIMP4 (TIMP
Metallopeptidase Inhibitor 4).
Description
CROSS REFERENCE TO RELATED APPLICATIONS
[0001] This application claims the benefit of U.S. Provisional
Patent Application No. 62/278,065, filed Jan. 13, 2016, which is
incorporated herein by reference in its entirety.
[0002] Provided herein is a method of making a vascular ECM
material, such as a gel, a vascular ECM material, and method of use
of the vascular ECM material, for example for treatment of
aneurysms and for vascularization or re-vascularization.
[0003] Free rupture or dissection of the ascending aorta is a
concerning clinical problem that occurs in up to 2.5 million
patients per year worldwide. Such aortic catastrophe is often
fatal, can occur without warning, and the only treatment option is
emergent aortic replacement. This biomechanical weakening of the
aortic wall is often precipitated by formation of thoracic aortic
aneurysm (TAA). TAA involves medial matrix degeneration but the
inciting mechanisms of aneurysm formation are mostly unknown.
Furthermore, there are currently no known strategies to regenerate
tissue deficits in the aortic wall. Remodeling of the vasa vasorum,
the microvascular network in the adventitia and decreased
expression of angiogenic signaling targets are associated with
TAA.
[0004] Extracellular matrix (ECM) bioscaffolds are tissue-specific
biomaterials with inherent bioactivity and native structural
features. These properties enable their desirable use as
three-dimensional in vitro cell culture substrates for biologic
discovery of cellular mechanisms or as disease models. Certain
decellularized tissues show promise for therapeutic tissue
regeneration in a variety of applications. Development of
decellularized native tissues has led to the production of
tissue-engineered scaffolds which retained basement membrane
proteins such as collagen type IV, laminin, and fibronectin that
enhance cellular adhesion and invoke signaling to influence
cellular differentiation and regenerative potential. Growth factors
including transforming growth factor-beta, basic fibroblast growth
factor (FGF), hepatocyte growth factor and vascular endothelial
growth factor (VEGF) persist in their bioactive form within ECM
bioscaffolds after sterilization. Additionally, degradation of ECM
bioscaffolds releases matricryptic peptides that invoke biologic
activity. ECM bioscaffolds guide stem cell differentiation through
growth factor retention and unique matrix compliance, which
together comprise tissue-specific microenvironments that are
advantageous for regeneration.
SUMMARY
[0006] Provided therefore are methods for preparing hydrogels from
solubilized vasculature-derived extracellular matrix (ECM)
compositions useful as in vitro cell culture substrates or in vivo
biomaterials for tissue repair in cardiovascular applications. The
extracellular matrix (ECM) of blood vessels provides essential
signaling for tissue-specific cell behavior including maintenance
of cell phenotype, differentiation, stem cell self-renewal, and
regulates overall tissue homeostasis and function. This invention
embodies a method wherein decellularized ECMs from blood vessels
(e.g. porcine or human aorta adventitia in one aspect) are
formulated into hydrogels and can be used as substrates for in
vitro cell culture and in vivo tissue regeneration.
[0007] The compositions and methods described herein solve the
problem of inadequate biomaterials to promote vasculogenesis. In
one aspect, provided herein is a native biologic substrate for
discovery biology in the aortic wall and its associated
microvasculature. The benefit of the compositions and methods
provided herein is that it is more representative of native
physiology than current products in the research marketplace (e.g.
Matrigel). The described compositions and methods are useful for
providing a research product for discovery biology and for the
potential for clinical translation as a therapeutic biological
material for the treatment of cardiovascular pathologies.
[0008] The compositions and methods provided herein utilize
vascular extracellular matrix (ECM) as the starting material for
the hydrogel and in one aspect, contain no synthetic polymer
components or cells. A unique advantage is the availability from
porcine, ovine or bovine sources. As indicated below, vascular ECM,
e.g. aortic adventitial tissue, requires a unique method of
derivation and formulation to produce a hydrogel.
BRIEF DESCRIPTION OF THE DRAWINGS
[0009] FIG. 1 provides photographs of western blotting analysis for
elastin and type I collagen of the adventitial ECM (AdvECM) gel
preparation of Example 1.
[0010] FIG. 2: Human endothelial cell proliferation. Cells were
cultured for 12 hr in the presence or absence of 50, 100 and 250
.mu.g/mL porcine adventitial ECM digest. Cell proliferation was
measured using an MTT
([3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide])-based assay. * Significant from cells cultured in basal
medium conditions alone (0 .mu.g/mL pAdvECM), p<0.05.
[0011] FIG. 3. Microvascular remodeling, or pathological increase
in luminal diameter and vessel wall thickness, is associated with
aneurysm in human aorta. Histological evidence of increased luminal
diameter in thoracic aortic aneurysm (TAA, B) vs. Non-aneurysmal
(NA, A, C) and increased wall thickness (D-F). Scale bar=100
.mu.m.
[0012] FIG. 4. Aortic ECM. A) Decellularized porcine aorta. B)
Aortic cross-section revealing complete removal of cell nuclei
(DAPI, blue) amidst intact elastic layers (C, Autofluoresence,
green). D) Lyophilized powdered ECM. E) Scanning electron
micrograph of 10 mg/mL adventitial hydrogel film revealing a
fibrous microstructure, scale bar=1 .mu.m. F) Optical density
(O.D.) of ECM gels over time. G) Rate of gelation for porcine and
human vascular ECMs on par with other ECMs (porcine sub-intestinal
submucosa (SIS)). Lines represent and normalized O.D. readings as a
measure of gel formation over time.
[0013] FIG. 5: Human endothelial cell proliferation. Cells were
cultured for 18 hr in the presence or absence of 5, 10, 25, 50, 100
and 250 .mu.g/mL pAdvECM. Cell proliferation was measured using an
MTT-based assay. * Significant from cells cultured in basal medium
conditions alone (0 .mu.g/mL pAdvECM), p<0.02. Results displayed
are representative of three independent experiments with two
different batches of pAdvECM.
[0014] FIG. 6. Endothelial cell migration. A) Wounded cell
monolayers cultured in the presence of pAdvECM demonstrated
increased wound closure over 18 hr when compared with untreated
cells cultured in their basal growth medium. B) Area under the
curves (AUC) in (A).
[0015] FIG. 7. Endothelial cell branching in vitro. Human
endothelial cells (12.5.times.104) were seeded on pAdvECM-spiked
growth factor-reduced Matrigel substrates and cultured for up to 18
hr. Cells cultured on Matrigel alone (A) formed tube-like
structures of relatively short length while pAdvECM-spiked Matrigel
increased the length of tube-like structures (B, D). Number of
tube-like structures was unchanged among cells cultured on
pAdvECM-treated and non-treated Matrigel substrates. *p<0.03,
n=3.
[0016] FIG. 8. Photographs and photomicrographs of two methods of
deposition of the hydrogel materials described herein as described
in Example 4.
[0017] FIG. 9. Preparation and characterization of pAdvECM
bioscaffolds. A) pAdvECM bioscaffold as a lyophilized ground
powder. B) Hydrogel formation from pH-neutralized pepsin-digested
pAdvECM bioscaffolds after 1 hr at 37.degree. C. C) DNA extracts
from 1.2 mg total tissue weight were qualitatively analyzed using
ethidium bromide-containing agarose gel electrophoresis. pAdvECM
Bioscaffold and SIS groups showed marked reduction of DNA content
compared to native aortic tissue.
[0018] FIG. 10. Scanning electron microscopy of porcine and human
adventitial ECM hydrogels. Decellularized tissue and ECM hydrogels
were fixed in 2.5% glutaraldehyde and processed for scanning
electron microscopy. Representative micrographs showing
decellularized human adventitia (Adv) (A-B), human Adv hydrogel
(C-D), porcine Adv hydrogel (E-F) and porcine small intestinal
submucosa (SIS) hydrogel (G-H) at 5,000.times. (A, C, E) and
10,000.times. (B, D, F) magnifications. All scale bars=1 .mu.m.
[0019] FIG. 11. Turbidimetric gelation kinetics of ECM hydrogels.
Gelation of pH-neutralized ECM digests was monitored using optical
density (O.D.) readings at 405 nm at 37.degree. C. for 90 min. A)
Porcine adventitia (Adv) (4, 8 and 16 mg/mL). B) Normalized
turbidimetric gelation kinetics of porcine SIS (8 mg/mL), human Adv
and porcine Adv (16 mg/mL).
[0020] FIG. 12. FGF2-mediated stimulation of primary endothelial
cell proliferation by ECMs. Primary human adventitia-derived
endothelial cells were cultured in the presence of 10 .mu.g/mL
porcine adventitial (pAdv, solid bars) or porcine small intestinal
submucosa (pSIS, gray bars) ECM. Cells in their basal culture
medium, FGF2 inhibitor alone (100 nM PD173074 in DMSO), or an
equivalent volume of DMSO and digestion buffer (1 mg/mL pepsin in
0.01 N HCl) served as controls (open bars). Quantification of MTS
[3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl-
)-2H-tetrazolium] conversion was performed after 72 hr of exposure
to the above conditions using a commercial assay and results were
expressed as percent change of untreated cells. One representative
of three independent experiments is displayed. Bars represent mean
of four assay replicates.+-.standard deviation. * indicates
p<0.05 when compared with untreated condition, **indicates
p<0.02, and # indicates p<0.005.
[0021] FIGS. 13A-13C. Effect of ECM bioscaffolds on network
formation of tube-like structures in vitro. FIG. 13A--Human
adventitia-derived endothelial cells were cultured on growth factor
reduced-Matrigel substrates: (A) DMSO, 0.05% (v/v), (B) Digestion
buffer (1% (w/v) Pepsin in 0.1 N HCl), (C) pAdv ECM, and (D) pSIS
ECM. FGF2 inhibitor PD173074 (100 nM) was added to the culture
medium of above treatments shown in parallel wells (E-H). A-H: One
representative 10.times. field is shown, selected from one of three
replicates of two independent experiments. All scale bars=50 .mu.m
for (A-H). Quantification of the number (FIG. 13B) and total length
(FIG. 13C) of tube-like structures from 5.times.5 stitched fields
captured at 10.times. for non-ECM-supplemented (open bars), pAdv
(solid bars) and pSIS (gray bars) ECM-supplemented substrates in
the absence and presence of PD173074. Bars represent mean of three
assay replicates .+-.standard deviation. Images and graphs
represent data from one of two independent experiments.
*Significant from pepsin HCl, p<0.02; #Significant from pAdv
ECM-treated cells in the absence of PD173074, p<0.03.
[0022] FIGS. 14A-14D. Effect of ECM bioscaffolds on angiogenesis in
vivo. FIG. 14A) Representative bright field images of scaffolds
before (Time 0) and after (72 hr) incubation on the chorioallantoic
membrane (CAM) of the chick embryo. The pro-angiogenic response to
pSIS and pAdv ECM-containing fibrin scaffolds (250 .mu.g/mL) is
revealed by the spoke-wheel pattern along the perimeter of the
scaffolds. There was no appreciable angiogenic response detected
around scaffolds loaded with digestion buffer (1% (w/v) pepsin in
0.1 N HCl) or DMSO. Addition of the FGF2 inhibitor PD173074 (100
nM) abrogated the angiogenic response to pAdv ECM. Addition of the
inhibitor vehicle only (DMSO) did not alter the angiogenic response
to pAdvECM. All scale bars for FIG. 14A=5 mm. FIG. 14B)
Representative histological cross-sections of CAM assay scaffolds.
The CAM vasculature was visualized using injected tomato
lectin-Dylight.RTM. 650 (red) and nuclei are labeled with Hoechst
dye (blue). A dashed white line denotes the scaffold/CAM interface.
Scaffolds loaded with digestion buffer alone exhibited no vessel
invasion. pSIS ECM (250 .mu.g/mL) stimulated invasion of new
vasculature (denoted by arrowheads) toward the scaffold as did pAdv
ECM in a dose-dependent manner for concentrations 50-250 .mu.g/mL.
The maximum tested dose of pAdv ECM (500 .mu.g/mL) inhibited
invasion of blood vessels into the scaffold. FIG. 14C) Addition of
DMSO did not alter pAdvECM induced invasion of blood vessels and
FGF2 inhibitor PD173074 blocked the effect of pAdv ECM loaded
scaffolds. All scale bars in FIG. 14B and FIG. 14C=500 .mu.m.
*Avascular zone comprised of lectin-negative cells. FIG. 14D).
Representative histological cross-sections showing chemoattraction
of lectin--negative cells in an avascular zone (*) adjacent to
invading lectin-positive cells (arrowheads) in pAdvECM loaded
fibrin scaffold (250 .mu.g/mL) (i) and inhibition of invasion of
lectin-positive cells in 500 .mu.g/ml pAdv ECM-loaded fibrin
scaffold (ii). (*) avascular zone comprised of lectin-negative
cells. All scale bars for FIG. 14D=20 .mu.m.
[0023] FIG. 15. Protein array-based profile of angiogenesis-related
proteins. Lyophilized ECM bioscaffolds (300 .mu.g total protein)
were evaluated for the presence of 55 angiogenesis-related proteins
in duplicate using the Human Angiogenesis Proteome Profiler Array.
Densitometric values are provided in FIG. 16. Images for porcine
and human ECM blots reflect exposure times of 20 min and 10 min
respectively. Dashed line boxes=positive control reference spots.
Dotted line boxes=negative control reference spots.
[0024] FIGS. 16A and 16B: Angiogenesis-related protein array.
Decellularized adventitia from normal (n=7 patients pooled) and
aneurysmal (n=28 pooled patients) human aorta, porcine adventitia
and SIS were analyzed for 55 angiogenesis-related proteins. Values
represent mean pixel density of two assay replicates .+-.standard
deviation (S.D.) for chemiluminescence detected after 5 (human
ECMs) or 14 (porcine ECMs) minutes of exposure. * p<0.05 when
compared with porcine adventitia; #p<0.05 when compared with
normal human aortic adventitial specimens.
[0025] FIG. 17. Representative bright-field images of scaffolds
before (Time 0) and after (72 hr) incubation on CAM. Angiogenic
response shown by the spoke-wheel appearance of vessels around
fibrin scaffolds loaded with all doses of pAdv ECM (50, 100 and 500
.mu.g/mL). (All scale bars=5 mm.
[0026] FIG. 18. Photograph (A) and photomicrographs (B) showing the
results described in Example 7. (A) shows that pAdv ECM-loaded
fibrin plug invoked an angiogenic response. (B) shows
Representative H&E-stained paraffin-embedded sections reveal
more cell infiltration within pSIS and pAdv ECM-loaded fibrin
scaffolds (denoted by an asterix) when compared with buffer loaded
scaffolds, as described in Example 7. For (B), scale bars=500 .mu.m
for left side panels and 50 .mu.m for right side panels.
DETAILED DESCRIPTION
[0027] The use of numerical values in the various ranges specified
in this application, unless expressly indicated otherwise, are
stated as approximations as though the minimum and maximum values
within the stated ranges are both preceded by the word "about". In
this manner, slight variations above and below the stated ranges
can be used to achieve substantially the same results as values
within the ranges. Also, unless indicated otherwise, the disclosure
of these ranges is intended as a continuous range including every
value between the minimum and maximum values. For definitions
provided herein, those definitions refer to word forms, cognates
and grammatical variants of those words or phrases. As used herein
"a" and "an" refer to one or more.
[0028] As used herein, the term "patient" or "subject" refers to
members of the animal kingdom including but not limited to human
beings and "mammal" refers to all mammals, including, but not
limited to human beings.
[0029] As used herein, the "treatment" or "treating" of a wound or
defect means administration to a patient by any suitable dosage
regimen, procedure and/or administration route of a composition,
device or structure with the object of achieving a desirable
clinical/medical end-point, including attracting progenitor cells,
healing a wound, correcting a defect, etc.
[0030] As used herein, the terms "comprising," "comprise" or
"comprised," and variations thereof, are open-ended and do not
exclude the presence of other elements not identified. In contrast,
the term "consisting of" and variations thereof is intended to be
closed-ended, and excludes additional elements in anything but
trace amounts.
[0031] As used herein, the terms "extracellular matrix" and "ECM"
refer to a natural scaffolding for cell growth. ECM is a complex
mixture of structural and non-structural biomolecules, including,
but not limited to, collagens, elastins, laminins,
glycosaminoglycans, proteoglycans, antimicrobials,
chemoattractants, cytokines, and growth factors. In mammals, ECM
often comprises about 90.degree./a collagen, in its various forms.
The composition and structure of ECMs vary depending on the source
of the tissue. For example, small intestine submucosa (SIS),
urinary bladder matrix (UBM), liver stroma ECM, and dermal ECM each
differ in their overall structure and composition due to the unique
cellular niche needed for each tissue.
[0032] The ECM materials as described herein retain activity of at
least a portion of its structural and non-structural biomolecules,
including, but not limited to, collagens, elastins, laminins,
glycosaminoglycans, proteoglycans, antimicrobials,
chemoattractants, cytokines, and/or growth factors, such as,
without limitation, the adventitial ECM product as described in the
examples below. The activity of the biomolecules within the ECM can
be removed chemically or mechanically, for example, by
cross-linking and/or by dialyzing the ECM. In one aspect, the ECM
materials described herein essentially have not been cross-linked
and/or dialyzed, meaning that the ECM has not been subjected to a
dialysis and/or a cross-linking process, or conditions other than
decellularization processes or processes that occur as part of
storage and handling of ECM prior to solubilization, as described
herein. Thus, in one aspect, the ECM material is not cross-linked
and/or dialyzed in anything but a trivial manner which does not
substantially affect the gelation and functional characteristics of
the ECM material in its uses described herein.
[0033] ECM is prepared by the decellularization and/or
devitalization of tissues prior to use. In one aspect,
decellularization is performed to prevent a pro-inflammatory
response. As such, in one aspect, a decellularized or devitalized
ECM product refers to ECM material that is decellularized to the
extent that a pro-inflammatory response, and thus growth of
fibrotic tissue is not elicited to any substantial degree in favor
of constructive remodeling.
[0034] By "bio compatible", it is meant that a device, scaffold
composition, etc. is essentially, practically (for its intended
use) and/or substantially non-toxic, non-injurous or non-inhibiting
or non-inhibitory to cells, tissues, organs, and/or organ systems
that would come into contact with the device, scaffold,
composition, etc.
[0035] As used herein, the term "derive" and any other word forms
or cognates thereof, such as, without limitation, "derived" and
"derives", refers to a component or components obtained from any
stated source by any useful method. For example and without
limitation, generically, an ECM-derived gel refers to a gel
comprised of components of ECM obtained from any tissue by any
number of methods known in the art for isolating ECM. In another
example, mammalian tissue-derived ECM refers to ECM comprised of
components of a particular mammalian tissue obtained from a mammal
by any useful method.
[0036] The methods described herein involve preparation of ECM or
an ECM gel. The ECM gel is reverse gelling, or can be said to
exhibit reverse thermal gelation, in that it forms a gel upon an
increase in temperature. As the temperature rises above a certain
temperature in a reverse gel, a hydrogel is formed. The general
concept of reverse gelation of polymers and, e.g., its relation to
lower critical solution temperature (LCST) are broadly known in the
chemical arts. The ECM compositions described herein are prepared,
for example, from decellularized or devitalized, intact ECM as
described below. An ECM gel is prepared by digestion of the ECM
material with an acid protease, neutralization of the material to
form a pre-gel, and then raising the temperature of the pre-gel
above a gelation temperature, for example the LCST of the pre-gel,
to cause the pre-gel to gel. As used herein, the term "gel"
includes hydrogels. The transition temperature for
acid-protease-digested from solution to gel is typically within the
range of from 10.degree. C. to 40.degree. C. and any increments or
ranges therebetween, for example from 20.degree. C. to 35.degree.
C. For example, the pre-gel can be warmed to 37.degree. C. to form
a hydrogel.
[0037] Tissue for preparation of ECM, ECM-derived pre-gel
solutions, and gels as described herein may be harvested in any
useful manner. According to various aspects, the ECM materials
described herein are prepared from vascular adventitia, such as
arterial or aortic adventitia. For example and without limitation,
in one aspect, the ECM material is prepared from harvested porcine
aorta, and in another, from human aorta. The adventitia is
dissected from the harvested tissue and is optionally frozen. Aorta
tissue is obtained by any suitable method, for example by manually
isolating from the surrounding tissue. In one aspect, the aortic
tissue is not obtained from aneurysmal tissue.
[0038] Decellularized or devitalized ECM can be dried, either
lyophilized (freeze-dried) or air dried. The ECM composition is
optionally comminuted at some point, for example prior to acid
protease digestion in preparation of an ECM gel, for example prior
to or after drying. The comminuted ECM can also be further
processed into a powdered form by methods, for example and without
limitation, such as grinding or milling in a frozen or freeze-dried
state. As used herein, the term "comminute" and any other word
forms or cognates thereof, such as, without limitation,
"comminution" and "comminuting", refers to the process of reducing
larger particles, e.g., of dried ECM, into smaller particles,
including, without limitation, by tearing, grinding, blending,
shredding, slicing, milling, cutting, shredding, shearing, and
pulverizing. ECM can be comminuted while in any form, including,
but not limited to, hydrated forms, frozen, air-dried, lyophilized,
powdered, sheet-form.
[0039] In order to prepare solubilized ECM tissue, ECM, for example
comminuted ECM, is digested with an acid protease in an acidic
solution to form a digest solution. As used herein, the term "acid
protease" refers to an enzyme that cleaves peptide bonds, wherein
the enzyme has increased activity of cleaving peptide bonds in an
acidic pH. For example and without limitation, acid proteases
include pepsin and trypsin and mixtures thereof.
[0040] As an example, the digest solution of ECM is kept at a
constant stir for a certain amount of time at room temperature. In
one aspect, the pH is maintained at less than pH 4.0 or at pH
2.0.+-.0.3 during acid protease digestion of the decellularized
aortic adventitial tissue as described herein. The ECM digest can
be used immediately or can be stored at -20.degree. C. or frozen
at, for example and without limitation, -20.degree. C. or
-80.degree. C. In certain aspects, the ECM digest is snap frozen in
liquid nitrogen. To form a "pre-gel" solution, the pH of the digest
solution is raised to a pH between 6.8 and 7.8. The pH can be
raised by adding one or more of a base or an isotonic buffered
solution, for example and without limitation, NaOH or PBS at pH
7.4. The method optionally does not include a dialysis step prior
to gelation, yielding a more-complete ECM-like matrix that
typically gels at 37.degree. C. more slowly than comparable
collagen or dialyzed ECM preparations. The gel therefore retains
more of the qualities of native ECM due to retention of many native
soluble factors, such as, without limitation, cytokines. These
factors contribute to chemoattraction of cells and proper
rearrangement of tissue at the site of injury, rather than a
fibrotic response that leads to unwanted scarring. In other
embodiments, the ECM is dialyzed prior to gelation to remove
certain soluble components.
[0041] As used herein, the term "isotonic buffered solution" refers
to a solution that is buffered to a pH between 6.8 and 7.8, e.g.,
pH 7.4, and that has a balanced concentration of salts to promote
an isotonic environment. As used herein, the term "base" refers to
any compound or a solution of a compound with a pH greater than 7.
For example and without limitation, the base is an alkaline
hydroxide or an aqueous solution of an alkaline hydroxide. In
certain embodiments, the base is NaOH, or NaOH in PBS. This
"pre-gel" solution can, at that point be incubated at a suitably
warm temperature, for example and without limitation, at about
37.degree. C. to gel.
[0042] In the method of preparing an ECM gel, the ECM may be
partially or completely digested with the acid protease, such as
pepsin. The digested ECM is then neutralized to a pH of 6.8-7.8.
e.g., 7.2-7.6, or 7.4 and the neutralized and digested ECM material
is gelled by incubation at a temperature at which the material
gels, e.g., at a temperature above 20, 25, 30, or 35.degree. C.,
such as at 37.degree.. The degree of digestion can be determined by
comparison on a gel, or by ascertaining the degree of degradation
of hyaluronic acid, for example by Western blot (anti-hyaluronic
acid antibodies are commercially-available from multiple sources)
or chromatographic methods, as are broadly known. For example in a
partial digestion, hyaluronic acid is digested less than 50%, 40%,
30%, 25%, 20% or 10%.
[0043] Therefore, according to one aspect of the invention, an ECM
composition is provided comprising devitalized,
acid-protease-digested aortic adventitial tissue, having a pH of
from 6.8 to 7.8. In one aspect, the devitalized,
acid-protease-digested aortic adventitial tissue is not dialyzed or
chemically crosslinked--meaning at no stage during the processing
of intact tissue to produce the devitalized, acid-protease-digested
aortic adventitial tissue has the material been dialyzed or
cross-linked by addition of a chemical cross-linking agent, as is
common in the production of certain devitalized ECM materials.
[0044] Unique characteristics of the aortic adventitial ECM
composition are described below. In one aspect, the aortic
adventitial ECM gel is more porous than comparative ECM gels. For
example, in FIG. 10, aortic adventitial ECM gel (panels C-F) is
shown to have increased length and linearity of fibers as compared
to SIS ECM gel prepared by a comparable method (panels G and H).
FIGS. 15 and 16 show the unique composition of the aortic
adventitial ECM gel composition as compared to a similarly-prepared
SIS ECM gel composition, with significantly lower (at least 50%
lower) amounts of FGF-1 and FGF-2, increased amounts of HB-EGF
(Heparin Binding EGIF Like Growth Factor, 3%), and decreased
amounts of various other proteins, e.g. (Ratios of pAdv: pSIS):
Angiopoietin 2--0.95; Endostatin--0.96; IGFBP1 (Insulin Like Growth
Factor Binding Protein 1)--0.9; PTX3 (Pentraxin 3)--0.91;
Prolactin--0.96; Serpin B5--0.87; and TIMP4 (TIMP Metallopeptidase
Inhibitor 4)--0.92.
[0045] In one aspect, the composition is cell-free, meaning the
composition comprises no living cells, and is therefore sterile,
and is optionally sterilized or disinfected. The composition can be
terminally sterilized, for example by sterilization by, for example
and without limitation, exposure to ethylene oxide (EtO) gas, gamma
irradiation, or electron beam radiation, and in one aspect when in
a dried or lyophilized state (see, e.g., WO 2015/143310,
incorporated herein by reference for its technical disclosure of
methods of terminally-sterilizing ECM gels). The composition is
typically disinfected with peracetic acid, as described herein.
[0046] In use, the ECM gel can be injected, sprayed, painted,
poured, or otherwise applied to a surface of a tissue, e.g., any
blood vessel, that is, the entire vascular network, such as,
without limitation: the abdominal aorta or descending aorta; the
ascending aorta; the aortic arch; an iliac artery or vein, such as
a common, interior, or exterior iliac artery or vein; a carotid
artery; a jugular vein; a subclavian artery or vein; a
brachiocephalic artery or vein (brachiocephalic trunk artery or
vein); the inferior vena cava; superior vena cava; and/or a
peripheral blood vessel of a patient. Depending on the final use of
the product, the composition may be applied or administered in a
variety of ways, either as a dry, e.g., lyophilized powder, a
solution, a gel, a foam, etc.
[0047] The composition can be administered by itself, or with a
device or composition. For example, the composition can be absorbed
into, adsorbed onto, mixed into, or otherwise co-administered with
a cell-growth scaffold, such as an isotropic or anisotropic mass of
fibers of synthetic and/or natural polymer(s), such as an
electrodeposited, wet or dry spun, 3D printed, molded, or otherwise
formed polymeric structure prepared from biocompatible polymeric
materials, as are broadly known in the regenerative medical field,
such as collagen, polyester (PE), polyurethane (PU), poly(ester
urethane) urea (PEUU), poly(ether ester urethane) urea (PEEUU),
poly(ester carbonate urethane)urea PECUU), and poly(carbonate
urethane)urea (PCUU) copolymers, and other suitable polymeric
materials, such as are disclosed, for example and without
limitation in U.S. Pat. Nos. 8,535,719; 8,673,295; 8,889,791;
8,974,542 and 9,023,972.
[0048] Additional non-limiting examples of useful polymer
compositions for use in the compositions described herein include:
polyolefin (polyalkene), polycarbonate, polyanhydride, polyether,
polyurea, polyurethane, polyketone, and fluoropolymers. In one
aspect, the polymer composition is bioerodible. Non-limiting
examples of biocompatible, bioerodible, elastomeric (co)polymer
compositions including PEUU, PEEUU, PECUU, and PCUU. Other useful
(co)polymers include, without limitation: polymers comprising
monomers of alpha-hydroxy acids; polylactides, such as
poly(lactide-co-glycolide), poly(L-lactide-co-caprolactone),
polyglycolic acid, poly(dl-lactide-co-glycolide),
poly(l-lactide-co-dl-lactide); other polyesters including
polyhydroxybutyrate, polyhydroxyvalerate, polydioxanone, and
polyglactin; polylactones including polycaprolactone;
polyglyconate, poly(glycolide-co-trimethylene carbonate),
poly(glycolide-co-trimethylene carbonate-co-dioxanone).
[0049] The compositions described herein also can be mixed into
polymeric compositions prior to or along with deposition of
polymeric fibers or formation of structures. Alternatively, where
the ECM product is not formed into a gel. ECM gel and/or synthetic
polymers may be absorbed into, adsorbed onto or otherwise combined
with the ECM product. In one aspect, a composition as described
herein is applied to and delivered from an ECM material, such as
any commercial ECM material, such as those described herein.
[0050] Likewise, the compositions described herein can be applied
to or incorporated into, by any suitable method, a non-woven
material, such as a bandage, a suture, an implant, such as a
ceramic, metal, or polymeric implant, for example a prosthesis,
artificial or otherwise-modified vessel, a valve, an intraocular
lens, a tissue transplant or implant.
[0051] As used herein, the term "coat", and related cognates such
as "coated" and "coating," refers to a process comprising of
covering an organic, inorganic, or living structure, or
combinations thereof, with a composition described herein. For
example and without limitation, coating of an inorganic structure
with an ECM-derived gel can include methods such as pouring,
embedding, layering, dipping, spraying. Ultrasonication may be used
to aid in coating of an inorganic structure with the ECM-derived
gel. As used herein, the term "ultrasonication" refers to the
process of exposing ultrasonic waves typically with a frequency
higher than 15 kHz and lower than 400 kHz. Organic structures
include both synthetic and natural polymer compositions including
devitalized tissue, proteinaceous compositions such as collagen,
and synthetic polymer compositions, such as PEUU, PEEUU, PCUU, and
PECUU, as indicated above. Living tissue may be any living tissue
whether or not located in situ within a patient, or dissected. For
example, the compositions and materials described herein may be
applied (in situ) to an existing blood vessel, such as the
descending aorta, in situ within a patient's abdomen or thoracic
cavity. In one aspect, a living, dissected blood vessel is treated
with the described compositions, such as soaked, sprayed, and/or
wrapped, prior to re-implantation to restore blood flow in a bypass
grafting procedure. In one example, the bypass grafting procedure
is a cardiac bypass procedure and the composition is applied to,
for example and without limitation, a vein, such as a saphenous
vein
[0052] In a further aspect, the composition is combined with other
compositions to form a composite structure. The other compositions
can be other biocompatible polymer compositions, in which the
adventitial ECM gel described herein contains particles of the
other biocompatible polymer, or the adventitial ECM gel is
dispersed, either homogeneously or non-homogeneously (e.g., as
microparticles or nanoparticles) within the other polymer. In one
aspect, the other biocompatible polymer is a fibrin plug having gel
particles of the described adventitial ECM dispersed throughout. In
another aspect, the other biocompatible polymer is a different ECM
gel into which the described adventitial ECM gel is mixed either
homogeneously or non-homogeneously. Other biocompatible particles
include natural polymer compositions, such as, without limitation,
fibrin, or synthetic polymers, such as described above.
[0053] In another aspect, the composition is coated onto a
biocompatible structural material, such as a metal, an inorganic
calcium compound such as calcium hydroxide, calcium phosphate or
calcium carbonate, or a ceramic composition. Non-limiting examples
of suitable metals are cobalt-chrome alloys, stainless steel
alloys, titanium alloys, tantalum alloys, titanium-tantalum alloys,
which can include both non-metallic and metallic components, such
as molybdenum, tantalum, niobium, zirconium, iron, manganese,
chromium, cobalt, nickel aluminum and lanthanum, including without
limitation, CP Ti (commercially pure titanium) of various grades or
Ti 6Al 4V (90% wt. Ti, 6% wt. Al and 4% wt. V), stainless steel
316, Nitinol (Nickel-titanium alloy), titanium alloys coated with
hydroxyapatite. Metals are useful due to high strength,
flexibility, and biocompatibility. Metals also can be formed into
complex shapes and many can withstand corrosion in the biological
environments, reduce wear, and not cause damage to tissues. In one
non-limiting example, the metal is femoral or acetabular component
used for hip repair. In another example, the metal is a fiber or
other protuberance used in permanent attachment of a prosthesis to
a patient. Other compositions, including ceramics, calcium
compounds, such as, without limitation, aragonite, may be
preferred, for example and without limitation, in repair of or
re-shaping of skeletal or dental structures. Combinations of metal,
ceramics and/or other materials also may prove useful. For
instance, a metal femoral component of a hip replacement may
comprise a ceramic ball and/or may comprise a plastic coating on
the ball surface, as might an acetabular component.
[0054] In certain aspects, the composition is used for release of
one or more therapeutic agents within a patient's body and/or
incorporates one or more therapeutic agents. For example, at least
one therapeutic agent is added to the composition described herein
before it is implanted in the patient or otherwise administered to
the patient, for example, a therapeutic agent is added to the
described polyelectrolyte pair as they are combined. Generally, the
therapeutic agents include any substance that can be coated on,
embedded into, absorbed into, adsorbed to, or otherwise attached to
or incorporated onto or into the composition or material described
herein, or incorporated into a drug product that would provide a
therapeutic benefit to a patient. Non-limiting examples of such
therapeutic agents include antimicrobial agents, growth factors,
emollients, retinoids, and topical steroids. Each therapeutic agent
may be used alone or in combination with other therapeutic agents.
For example and without limitation, a composition comprising
neurotrophic agents or cells that express neurotrophic agents may
be applied to a wound that is near a critical region of the central
nervous system, such as the spine.
[0055] In certain non-limiting aspects, the therapeutic agent is a
growth factor, such as a neurotrophic or angiogenic factor, which
optionally may be prepared using recombinant techniques.
Non-limiting examples of growth factors include basic fibroblast
growth factor (bFGF), acidic fibroblast growth factor (aFGF),
vascular endothelial growth factor (VEGF), hepatocyte growth factor
(HGF), insulin-like growth factors 1 and 2 (IGF-1 and IGF-2),
platelet derived growth factor (PDGF), stromal derived factor 1
alpha (SDF-1 alpha), nerve growth factor (NGF), ciliary
neurotrophic factor (CNTF), neurotrophin-3, neurotrophin-4,
neurotrophin-5, pleiotrophin protein (neurite growth-promoting
factor 1), midkine protein (neurite growth-promoting factor 2),
brain-derived neurotrophic factor (BDNF), tumor angiogenesis factor
(TAF), corticotrophin releasing factor (CRF), transforming growth
factors .alpha. and .beta. (TGF-.alpha. and TGF-.beta.),
interleukin-8 (IL-8), granulocyte-macrophage colony stimulating
factor (GM-CSF), interleukins, and interferons. Commercial
preparations of various growth factors, including neurotrophic and
angiogenic factors, are available from R & D Systems,
Minneapolis, Minn.; Biovision, Inc, Mountain View, Calif.;
ProSpec-Tany TechnoGene Ltd., Rehovot, Israel; and Cell
Sciences.RTM., Canton, Mass.
[0056] In certain non-limiting aspects, the therapeutic agent is an
antimicrobial agent, such as, without limitation, isoniazid,
ethambutol, pyrazinamide, streptomycin, clofazimine, rifabutin,
fluoroquinolones, ofloxacin, sparfloxacin, rifampin, azithromycin,
clarithromycin, dapsone, tetracycline, erythromycin, ciprofloxacin,
doxycycline, ampicillin, amphotericin B, ketoconazole, fluconazole,
pyrimethamine, sulfadiazine, elindamycin, lincomycin, pentamidine,
atovaquone, paromomycin, diclazaril, acyclovir, trifluorouridine,
foscarnet, penicillin, gentamicin, ganciclovir, iatroconazole,
miconazole, Zn-pyrithione, and silver salts such as chloride,
bromide, iodide and periodate.
[0057] In certain non-limiting aspects, the therapeutic agent is an
anti-inflammatory agent, such as, without limitation, an NSAID,
such as salicylic acid, indomethacin, sodium indomethacin
trihydrate, salicylamide, naproxen, colchicine, fenoprofen,
sulindac, diflunisal, diclofenac, indoprofen, sodium salicylamide;
an anti-inflammatory cytokine; an anti-inflammatory protein; a
steroidal anti-inflammatory agent; or an anti-clotting agents, such
as heparin. Other drugs that may promote wound healing and/or
tissue regeneration may also be included.
[0058] In certain non-limiting embodiments, cells are added to the
composition. Non-limiting examples of useful cells include: stem
cells, progenitor cells and differentiated cells; recombinant
cells; muscle cells and precursors thereof; nerve cells and
precursors thereof; mesenchymal progenitor or stem cells; bone
cells or precursors thereof, such as osteoprogenitor cells,
pre-adipocytes, etc.
[0059] Any useful cytokine, chemoattractant, drug or cells can be
mixed into, mixed with, co-applied or otherwise combined with any
composition as described herein. For example and without
limitation, useful components include growth factors, interferons,
interleukins, chemokines, monokines, hormones, angiogenic factors,
drugs and antibiotics. Cells can be mixed into the composition or
can be included on or within a substrate such as a biological
scaffold, combined with the composition. In either case, when the
substrate is seeded with cells, the cells can be grown and/or
adapted to the niche created by incubation in a suitable medium in
a bioreactor or incubator for a suitable time period to
optimally/favorably prepare the composition for implantation in a
patient. The substrate can be seeded with cells to facilitate
in-growth, differentiation and/or adaptation of the cells. For
example and without limitation, the cells can be autologous or
allogeneic with respect to the patient to receive the
composition/device comprising the gel. The cells can be stem cells
or other progenitor cells, or differentiated cells.
[0060] As used herein, the terms "drug" and "drugs" refer to any
compositions having a preventative or therapeutic effect, including
and without limitation, antibiotics, peptides, hormones, organic
molecules, vitamins, supplements, factors, proteins and
chemoattractants.
[0061] As used herein, the terms "cell" and "cells" refer to any
types of cells from any animal, such as, without limitation, rat,
mice, monkey, and human. For example and without limitation, cells
can be progenitor cells, such as stem cells, or differentiated
cells, such as endothelial cells and smooth muscle cells. In
certain embodiments, cells for medical procedures can be obtained
from the patient for autologous procedures or from other donors for
allogeneic procedures.
[0062] In a further aspect, a commercial kit is provided comprising
a composition described herein. A kit comprises suitable packaging
material and the composition. In one non-limiting embodiment, the
kit comprises a liquid, gelled or dried ECM in a vessel, which may
be the packaging, or which may be contained within packaging. The
vessel may be a vial, syringe, tube or any other container suitable
for storage and transfer in commercial distribution routes of the
kit. Likewise, a product, such as a device, gel, scaffolding,
suture, prosthetic, mesh, foam etc. including one or both of the
soluble or structural compositions described herein may be packaged
appropriately for commercial distribution.
[0063] According to one aspect of the invention, a method of
production of aortic ECM is provided. The method uses a
zwitterionic detergent, such as CHAPS or Betaines (any neutral
compound having both positive and negative charges), and includes
as a class detergents/surfactants such as
1-Dodecanoyl-sn-glycero-3-phosphocholine,
3-(4-tert-Butyl-1-pyridinio)-1-propanesulfonate,
3-(N,N-Dimethylalkylammonio)propanesulfonate, where alkyl is
typically a linear, aliphatic hydrocarbon, such as a linear
C.sub.6-22 saturated hydrocarbon,
3-(1-Pyridinio)-1-propanesulfonate, Surfactin, and other, as are
broadly-available from commercial sources, such as Sigma-Aldrich.
Anionic detergents are any useful detergents comprising a negative
charge, such as, without limitation, alkylbenzene sulfonates, bile
acids such as deoxycholic acid, and organosulfates, such as SDS.
Alternatives to Trypsin-EDTA are known, and other enzymes for cell
detachment and tissue dissociation, as are available commercially,
such as collagenase, hyaluronidase, elastase, papain, protease Type
XIV, alone or in combination, optionally with Trypsin, for example
from Sigma-Aldrich (e.g., Accutase.RTM.), and optionally chelating
agents other than EDTA may be used to equal effect.
[0064] As a first step, fresh aortic tissue is obtained and fat and
connective tissue is removed. Using any method, such as by use of
forceps or scissors as described below, or by any automated
mechanical process, the adventitial layer dissected from the medial
layer to produce aortic adventitia. The aortic adventitia is then
frozen and thawed. Next, the material is incubated in a
zwitterionic detergent and is typically washed. Washing is usually
done using PBS and/or water, or other solvents, such as alcohol as
is appropriate. The material is then incubated in a Trypsin-EDTA or
an equivalent for dissociating cells and tissue, typically followed
by washing. Next, the material is incubated in an anionic
detergent, typically followed by washing. The material is
subsequently disinfected, for example by treatment with peracetic
acid, and is then washed. The material is then dried, e.g. by
lyophilization, and is comminuted. In its dry state, the materials
are optionally sterilized. The dry, comminuted material is
rehydrated in an acid, such as HCl, .about.pH<4.0, from 1 to 4,
e.g. pH 1 to 2, for example 2.0.+-.0.3, and is digested with an
acid protease, such as pepsin, maintaining the pH of the solution
at within the active range for the protease, e.g., <4.0. from 1
to 4, from 1 to 2, e.g., 2.0.+-.0.3. Digestion may be partial or
complete. Partial digestion may be accomplished by use of shortened
acid protease digestion times, use of lower amounts of acid
protease in the reaction, and/or by digestion above the optimal pH
for the acid protease. Complete digestion is typically accomplished
at an optimal pH for the acid protease, for example at pH of 2.5 or
less, for example 2.0.+-.0.3. To form a gel, the acidic solution is
neutralized, e.g. to pH 6.8 to 7.8, to form a pre-gel solution, and
the solution is incubated at a higher temperature, such as at room
temperature (20.degree. C.-25.degree. C.) or 37.degree. C. (e.g.,
from 20.degree. to 50.degree. C., from 30.degree. to 45.degree. C.,
from 35.degree. to 42.degree. C., or at 37.degree. C..+-.5.degree.
C., 4.degree. 2, 3.degree. C., 2.degree. C., or P.degree. C.) to
form a gel. Prior to, during or after gelation, the pre-gel
solution can be sprayed, coated, mixed, layered, poured, injected
or otherwise deposited on a substrate or into a substrate, such as
a polymer, a ceramic, a metal, a tissue (ex vivo, or in vivo), a
different devitalized tissue product, such as a sheet of SIS ECM, a
non-woven material, a suture, or any other medically-useful
material. In one aspect, the acid protease digestion is incomplete,
but complete enough to produce a gel, leaving small particles of
undigested ECM material within the resultant gel, which would be
digested in situ during use of the composition--resulting in
delayed release of therapeutic compositions thereof.
[0065] According to another aspect, a method of treating an
aneurysm in a patient is provided, comprising administering to a
surface of a blood vessel having an aneurysm, a devitalized,
acid-protease-digested vascular adventitial, e.g., an aortic
adventitial tissue, having a pH of from 6.8 to 7.8, for example
prepared according to the method described herein. In one aspect,
the blood vessel is the descending, abdominal, or ascending aorta,
or aortic arch of the patient.
[0066] According to another aspect, a method of inducing
vascularization or re-vascularization in a patient is provided. The
method comprises administering to a living tissue, in viva or ex
vivo (e.g., in the case of a transplant) an acid protease-digested
vascular adventitial, e.g. aortic adventitial ECM pre-gel or gel
composition according to any aspect or embodiment provided herein,
resulting in vascularization, e.g., revascularization, of the
living tissue. In one aspect, the tissue is a wound in a patient,
such as skin wound, for example and without limitation, a diabetic
ulcer, such as a diabetic foot ulcer. In another aspect, the tissue
is bone tissue, for example damaged bone tissue or bone tissue
exhibiting osteoporosis. In another aspect, the tissue is
myocardium and/or vasculature thereof in a patient, for example a
wound or an infarct in a patient's myocardium.
EXAMPLES
[0067] Free rupture or dissection of the ascending aorta is a
concerning clinical problem that occurs in up to 2.5 million
patients per year worldwide. Such aortic catastrophe is often
fatal, can occur without warning, and the only treatment option is
emergent aortic replacement. A solution to this problem is offered
by an aorta-derived extracellular matrix hydrogel as a prophylactic
and minimally-invasive treatment option for patients at risk for
aortic rupture. This goal is bolstered by active hypothesis-driven
research defining what mechanisms cause endothelial dysfunction in
the setting of human aortic disease and how matrix-driven signaling
impacts vasculogenesis by local progenitor cells in the adventitia,
the outer layer of the aortic wall. This new knowledge drives the
development of a regenerative medicine approach to invoke
remodeling of the aortic wall itself, essentially repairing the
aorta from the outside-in through regeneration of the associated
microvascular network.
Example 1--Preparation of Adventitial Hydrogel
[0068] To study the influence of the adventitial extracellular
matrix (ECM) on vasa vasorum function, hydrogels were developed
from decellularized human and porcine aortic adventitia. Porcine
aortic specimens were obtained from commercial sources, while human
aorta was harvested during open aortic replacement operations with
IRB approval and informed patient consent. The adventitia was
delaminated from the medial layer and incubated in a zwitterionic
detergent (8 mM CHAPS, 1 M NaCl, and 25 mM EDTA) for 24 hr at
37.degree. C., followed by washing in PBS then in deionized water
for 2 hr. The adventitia was then submerged in an anionic detergent
(0.5% SDS, 1M NaCl, and 25 mM EDTA) for 24 hr, and 2 hours in
deionized water, followed by lyophilization, exposure to 70%
ethanol and rinsed with deionized water and PBS to rehydrate the
ECM. Complete decellularization of aortic tissue was confirmed by
absence of DAPI staining in paraffin-embedded sections. Following
lyophilization and grinding, ECM powder was digested in 0.01 N HCL
and pepsin for 24 hr. Western blotting analysis revealed that ECM
digests contain elastin and type I collagen (see, FIG. 1). Hydrogel
films were formed from neutralized ECM digests. Gelation kinetic
analyses demonstrated that peak gelation was reached within 90
minutes of incubation in a 37.degree. C. dry heat incubator.
Scanning electron microscopy revealed that hydrogel films exhibit
native ECM fiber-like microarchitecture. Aortic ECM hydrogels may
serve as cell culture substrates to study matrix-derived mechanisms
of microvascular dysfunction in the setting of aneurysm. The
clinical translation of this work is that aortic ECM hydrogels
might function as native biologic materials for tissue regeneration
in cardiovascular applications.
[0069] Porcine aortic adventitia was decellularized and digested as
described above. Human endothelial cells (P16) were seeded at a
density of 5.times.10.sup.3 cells/cm.sup.2 and cultured in the
presence of 0-250 .mu.g/mL porcine adventitial ECM digest (pAdvECM)
for 12 hours at 37.degree. C. in a humidified incubator. Cell
proliferation was measured using an MTT conversion assay (Cell
Titer, Promega) according the manufacturer's instructions. As shown
in FIG. 2, 50 .mu.g/mL pAdvECM digest increased human endothelial
cell proliferation (p<0.05) compared to endothelial cells
cultured in basal growth medium alone (endothelial growth medium,
Cell Applications). Whereas, higher doses of pAdvECM digest (250
.mu.g/mL) decreased cell proliferation (p<0.05). This noted
decrease in cell proliferation by higher doses of ECM digest may be
related to the acidic pH of the culture medium evidence by a noted
color change in the phenol-red containing medium upon addition
(data not shown). These data provide preliminary evidence that
decellularized pAdvECM digests exhibit mitogenic bioactivity and
can invoke endothelial cell proliferation, a necessary mechanism
for vasculogenesis.
Example 2--Microvascular Remodeling in the Aorta is Associated with
Thoracic Aortic Disease
[0070] Research revealed microvascular remodeling associated with
aneurysm in the ascending thoracic aorta. Note the paucity of
microvessels in specimens of aneurysmal aorta, along with increased
luminal area of existing vessels and wall thickening (FIG. 3).
Also, that the human aortic adventitia is home to a progenitor cell
niche, including endothelial and pericyte progenitor cells, the
precursors of microvasculature networks. This new knowledge
inspires a regenerative medicine approach as a minimally-invasive
treatment strategy for patients at risk for aortic rupture by
harnessing local progenitor cells for therapeutic microvascular
regeneration. Decellularized aortic extracellular matrices (ECMs)
described herein are proposed for use as stimuli for therapeutic
microvascular regeneration.
[0071] The vascular ECM hydrogel described herein is unique in both
method and composition (FIG. 4). Following decellularization of
mammalian vascular ECM (FIG. 4(A-C)), digestion of the lyophilized
and morcellated ECM (FIG. 4(D)) deviates substantially from
Freytes, D. O., et al. ((2008). "Preparation and rheological
characterization of a gel form of the porcine urinary bladder
matrix." Biomaterials 29(11): 1630-1637) in that pH is closely
monitored and tightly controlled to pH 2.0.+-.0.3. Cell-friendly
ECMs from porcine and human aorta have been optimized for hydrogel
formation with fibrous microarchitecture similar to native ECM
(FIG. 4(E)). Preliminary experiments demonstrate that vascular ECM
hydrogels reach peak gelation within 90 minutes in a dry heat
incubator at 37.degree. C. (FIG. 4(F)) with rates of gelation for
both porcine and human aortic ECMs being similar to that of porcine
sub-intestinal sub-mucosa (SIS) (FIG. 4(G)) and urinary bladder
matrix. (Freytes et al. 2008).
Example 3--Evaluation of Vascular ECM Bioactivities
[0072] Demonstrating the therapeutic potential of vascular-derived
extracellular matrices (ECMs) involves evaluating their bioactivity
as regulators of 1) cell proliferation 2) cell migration and 3)
endothelial branching. A series of experiments were performed to
address the above three functions.
[0073] Adventitia-Derived ECM is Mitogenic.
[0074] Porcine aortic adventitia was decellularized and digested as
previously described above to obtain extracellular matrix
(pAdvECM). Human endothelial cells (P16-18) were seeded at a
density of 5.times.10.sup.3 cells/cm.sup.2 and cultured in the
presence of 0-25 .mu.g/mL porcine adventitial ECM digest (pAdvECM)
for 2-18 hours at 37.degree. C. in a humidified incubator. Cell
proliferation was measured using an MTT conversion assay (Cell
Titer, Promega) according the manufacturer's instructions. From the
data shown in FIG. 5, 5-10 .mu.g/m, pAdvECM digest increased human
endothelial cell proliferation (p<0.02) compared to endothelial
cells cultured in basal growth medium alone (endothelial growth
medium, Cell Applications). These data provide preliminary evidence
that decellularized pAdvECM digests exhibit mitogenic bioactivity
and can invoke endothelial cell proliferation, an important
mechanism for vasculogenesis.
[0075] Adventitial-Derived ECM Stimulates Endothelial Cell
Migration.
[0076] The effect of pAdvECM digest on endothelial cell migration
was evaluated using an in vitro wound healing or "scratch test"
pilot assay. In brief, a scratch "wound" was made using a P20 pipet
tip in monolayer cultures of human endothelial cells at confluence,
followed by culture in the presence or absence of 25 .mu.g/mL
pAdvECM for up to 18 hr. Cells were placed within a stage-top
incubation chamber and maintained at 37.degree. C., 5% CO.sub.2 and
humidity. Images were obtained using phase-contrast light
microscopy on an inverted TE-2000 microscope (Nikon) every 10
minutes. Percent of wound closure over time was calculated from
images by creating binary thresholds using image analysis software
(NIS Elements 4.2, Nikon). We conclude from the data shown in FIG.
6 that treatment of endothelial cells with pAdvECM increased the
rate of cell migration, evidenced by the increased percentage of
wound closure when compared with cells in their basal culture
medium (negative control).
[0077] Adventitial-Derived ECM Enhanced Endothelial Cell
Branching.
[0078] The effect of pAdvECM on endothelial cell branching was
evaluated in vitro. Briefly, 0, 250, 500 or 1000 .mu.g/mL of
pAdvECM was combined with growth factor reduced-Matrigel.TM.
(Corning) and used to coat the surface of wells in a 48-well tissue
culture plate. The pAdvECM/Matrigel mixture (150 .mu.L) was allowed
to cure for 1 hr at 37.degree. C. prior to seeding of
12.5.times.104 cells/well in endothelial growth medium. We conclude
from the data shown in FIG. 7, that pAdvECM enhanced endothelial
cell branching on Matrigel substrates when compared with Matrigel
alone (p<0.03). While number of tube-like structures was
unchanged with pAdvECM treatment, their length was found to be
increased when compared with untreated cells cultured on Matrigel
substrate alone.
Example 4--Clinical Translation
[0079] Therapeutic efficacy of the hydrogel will be tested using
this spraying device in pre-clinical models in small (mouse:
sub-cutaneous vascularization) and large (rabbit and porcine:
aneurysm) animals. Hydrogels can be aerosolized for
minimally-invasive delivery. An ECM hydrogel can be sprayed or
basted onto a polyurethane-base tubular scaffold. Sprayed ECM
hydrogel was found to be dispersed within the wall of the tubular
scaffold, or as an outer sheath by simply "basting" the gel onto
the outer surface of the tubular scaffold as detected using a
picrosirius red stain for collagen with and without polarized light
(FIG. 8). This work is a vertical leap in the field by delivering
biologic materials to the aorta to harness local perivascular
progenitor cells that are capable of therapeutic
vasculogenesis--shifting focus to a minimally-invasive treatment
approach to invoke aortic regeneration in the setting of aneurysm
using aerosolized biological hydrogels.
Example 5--Preparation of Aortic ECM-Derived Hydrogels
[0080] The following is an exemplary and non-limiting protocol for
preparation of aortic ECM-derived hydrogels.
[0081] Solutions.
[0082] Zwitterionic Detergent: 5.895 g CHAPS
(3-[(3-Cholamidopropyl) dimethylammonio]-1-propanesulfonate) (8
mM); 70.08 g NaCl (1 M); 8.76 g EDTA (25 mM); and 1200 mL PBS.
Trypsin-EDTA: 1.2 g Trypsin (0.1%); 0.456 g EDTA (lx); and 1200 mL
PBS. Anionic Detergent: 70.08 g NaCl (1M); 8.76 g EDTA (25 mM);
6.228 g SDS (18 mM); and 1200 mL PBS. Peracetic Acid: 7.98 mL
Peracetic Acid stock (PAA, 0.1%); 1152 mL distilled water
(dH.sub.2O, 96%); and 48 mL 100% Ethanol (4%). 0.01 N Hydrochloric
Acid: 50 .mu.L 12 N HCl stock; and 9.95 mL dH.sub.2O. 5 N
Hydrochloric Acid: 4. 167 mL 12 N HCl solution; and 5.833 mL
dH.sub.2O.
[0083] Procedure 1: Cleaning of Fresh Aortic Tissue and Isolation
of Adventitial Layer.
[0084] Using blunt forceps and scissors, remove all extraneous fat
and connective tissue from fresh or frozen porcine or human aorta.
Ensure tissue does not dry out by hydrating tissue occasionally
with dH.sub.2O. Using blunt forceps, delaminate the adventitial
layer from the medial layer of aortic specimens to create sheets of
aortic adventitia. Delaminated aortic adventitia is cut into
.about.2.5.times.2.5 inch squares for decellularization. Remove 1
square from the middle and corner of a fresh (not decellularized)
section of fresh aorta, both to be snap frozen; 1 for histological
analysis, the other for future studies. To measure total wet weight
of aortic adventitial squares, gently dab tissue dry and weigh on
precision balance. The following protocol is optimized for
approximately 30 g of adventitial sheet squares (wet weight).
Freshly isolated tissue must be frozen at -80.degree. C. at least
overnight and allowed to thaw before processing.
[0085] Procedure 2: Decellularzation.
[0086] Place adventitial tissue in 1 L flask and fill with 800 mL
DI water. Place 1 L flask with adventitia on orbital shaker and run
at 300 rpm for 30 minutes. Remove D.I water and replace with fresh
D.I water (800 mL for adventitia). Repeat three more times (4 total
rinses, 2 hour duration on shaker). While tissue is on shaker begin
prep of Zwitterionic Detergent. Place Zwitterionic detergent in
37.degree. C. water bath 30 minutes prior to completion of tissue
shaking (ensures solution is at appropriate temperature for next
step). Upon completion of shaking remove and discard D.I water.
Transfer each tissue type to a separate 1-L flask. Fill adventitial
flask with 400 mL of warm Zwitterionic Detergent (400 mL per approx
30 g of tissue). Place flasks in 37.degree. C. shaking water bath.
Let flasks sit in rocking bath for 12 hours. After 12 hours in bath
replace Zwitterionic detergent. For replacement follow identical
procedure as initial Zwitterionic detergent prep. After replacing
Zwitterionic detergent replace flasks in warm shaking water bath
and allow incubation for another 12 hours (24 hours of total
Zwitterionic incubation). 30 minutes before completion of
incubation bring 2400 mL of IX PBS up to 37.degree. C. After
incubation completion remove flasks from shaking water bath and
properly discard Zwitterionic detergent. Rinse tissues with
37.degree. C.--1.times.PBS on rocking water bath for 15 minutes
(400 mL for adventitia). Replace 1.times.PBS and rinse on rocking
water bath for 15 more minutes (30 min total). Store tissue
overnight at 4.degree. C. in still dH.sub.2O. Transfer tissues to
clean flasks with 400 mL dH.sub.2O. Using the orbital shaker (300
rpm) shake the tissue for 1 hour. Replace dH.sub.2O and shake for
additional hour (2 hours total). 30 minutes before conclusion of
dH.sub.2O shake, prep Trypsin-EDTA solution and bring up to
37.degree. C. Empty and discard spent dH.sub.2O water. Replace with
400 mL Trypsin-EDTA solution. Incubate tissue in shaking water bath
for 30 minutes at 37.degree. C. Replace Trypsin-EDTA solution with
second batch of solution and incubate for 30 more minutes in
37.degree. C. shaking water bath (1 hour total). Dispose of
Trypsin-EDTA solution. Either clean or use new 1 L flasks. Transfer
tissues to new flasks. Fill flasks with 400 mL dH.sub.2O. Shake
flasks on orbital shaker at 300 rpm for 1 hour. Replace dH.sub.2O
and shake for additional hour (2 hours total). 30 minutes prior to
finishing dH.sub.2O rinse, begin prep of Anionic Detergent. Warm
anionic detergent to 37.degree. C. Discard spent dH.sub.2O and
replace with 400 mL Anionic Detergent). Place flasks in 37.degree.
C. shaking water bath for 12 hours. Repeat anionic detergent
incubation. Properly dispose of Anionic Detergent. Either clean or
obtain new 1 L flasks. Fill flasks with 400 mL 1.times.PBS. Shake
tissue and PBS solution on orbital shaker at 300 rpm for 15
minutes. Discard spent PBS. Repeat PBS wash. Store tissue overnight
at 4.degree. C. in still dH.sub.2O. Transfer tissues to clean
flasks with 400 mL of dH.sub.2O. Using the orbital shaker (300 rpm)
shake the tissue for 7 hours. Replace dH.sub.2O and shake for
additional 7 hours (14 hours total). Empty dH.sub.2O and fill
flasks with prepped Peracetic acid solution (400 mL). Shake flasks
on orbital shaker for 2 hours at 300 rpm. Properly dispose of
Peracetic acid. Clean or obtain new IL flasks. Fill flasks with IX
PBS (400 mL). Shake tissue on orbital shaker (300 rpm) for 15 min.
Discard spent PBS and fill flasks with dH.sub.2O (400 mL). Shake
tissue and dH.sub.2O on orbital shaker at 300 rpm for 15 minutes.
Replace dH.sub.2O and shake for additional 15 min (30 total).
Discard dH.sub.2O and fill with PBS (400 mL). 57. Shake on orbital
shaker for 15 minutes at 300 rpm. Expand samples on aluminum foil.
Remove two 0.5.times.0.5 cm.sup.2 sections from the middle and
corner of 3 total decellularized square sections for quality
control to confirm decellularization. From each decellularized
square sampled, snap freeze 1 section for histological sectioning
and 1 stored in a microfuge tube for future assays. Wrap samples
with aluminum foil and crimp edges. Freeze in -80.degree. C.
overnight. Transfer frozen samples to lyophilizer, and initiate
vacuum. Check samples after 2 days by handling: fully lyophilized
samples will be brittle, with little to no flexibility. If not
"brittle" by 2 days, lyophilize for an additional day and follow-up
after 24 hours to see if "brittle" tissue achieved. Once tissue
observed to be brittle, prep decellularized, lyophilized, brittle
samples by breaking squares into 0.5-0.75.times.0.5-0.75 cm.sup.2
pieces to facilitate tissue grinding.
[0087] Procedure 3: Grinding of Lyophilized Adventia.
[0088] Assemble grinder with 60 mesh screen to collect finely
ground adventitial powder. Add decellularized, lyophilized
adventitial pieces gradually to hopper on grinder, forcing tissue
through with wooden dowel. Once all tissue is ground, collect
powder and store at room temperature in a labeled, air-tight,
sealed container.
[0089] Procedure 4: Adventitial Powder Digestion.
[0090] Weigh out 0.5 g of lyophilized, ground adventitia powder
using a precision balance. Weigh out 100 mg of pepsin (Sigma) using
a precision balance. Add 45 .mu.L 5 N HCl. Confirm resulting pH 2
using acidic pH paper and matching to the pH 2 shade of red. Slowly
add pepsin to stirring pH 2, 0.01 N HCl solution. 5. Once pepsin is
solubilized in 0.01 HCl, gradually add all adventitial powder to
stirring pepsin-HCl solution. After all adventitial powder added to
solution, note the start time of digestion. Check and confirm pH of
2 at start of digestion. Allow to continue stirring at 900 RPM for
1.5 hours. While still stirring at 900 RPM, after 1.5 hours of
digestion, check pH of "digest". If pH is between 2-3, add 120
.mu.L of 5 N HCl. Confirm pH adjustment to 2 by matching to pH 2 on
pH paper. Continue to check pH of solution every 30 minutes for 1.5
hours, adding 20 .mu.L 5 N HCl to the solution if pH is observed
between 2-3. Continue stirring at 900 RPM for 15 hours. After 15
hours, increase stir of digest to 1100 RPM to compensate for
increased viscosity. Confirm pH is still 2. Continue stirring for
remaining 6 hours of 24 hour digest cycle. After 24 hours of
digestion, decrease RPM to 200 RPM to allow bubbles to rise out of
digest to surface of solution for 10 minutes. After 10 minutes at
200 RPM, store ECM digest in 500 .mu.L aliquots at -20.degree. C.
or transfer to ice and prepare hydrogels as below.
[0091] Procedure 5: Hydrogel Formation.
[0092] Keep, or thaw previously-frozen ECM digest on ice. Keep all
reagents on ice: 10.times.PBS, 0.1 N NaOH, 1 N NaOH, 1 N HCl. Mix
in the following order: 1 part 10.times.PBS, 1 part 0.1 NaOH and 8
parts ECM digest. Vortex to mix. Check pH and adjust to 6.8-7.8.
Add hydrogel to tissue culture wells, coverglass or molds and
incubate for 60-90 minutes in a 37.degree. C. dry heat incubator,
overnight in a humidified 37.degree. C. incubator or up to 8 hr at
room temperature.
Example 6--Perivascular Extracellular Matrix Hydrogels Mimic Native
Matrix Microarchitecture and Promote Angiogenesis Via Basic
Fibroblast Growth Factor
[0093] Extracellular matrix (ECM)-derived bioscaffolds have been
shown to elicit tissue repair through retention of bioactive
signals. Given that the adventitia of large blood vessels is a
richly vascularized microenvironment, we hypothesized that
perivascular ECM contains bioactive signals that influence cells of
blood vessel lineages. ECM bioscaffolds were derived from
decellularized human and porcine aortic adventitia (hAdv and pAdv,
respectively) and then shown have minimal DNA content and retain
elastin and collagen proteins. Hydrogel formulations of hAdv and
pAdv ECM bioscaffolds exhibited gelation kinetics similar to ECM
hydrogels derived from porcine small intestinal submucosa (pSIS).
hAdv and pAdv ECM hydrogels displayed thinner, less undulated, and
fibrous microarchitecture reminiscent of native adventitia, with
slight differences in ultrastructure visible in comparison to pSIS
ECM hydrogels. Pepsin-digested pAdv and pSIS ECM bioscaffolds
increased proliferation of human adventitia-derived endothelial
cells and this effect was mediated in part by basic fibroblast
growth factor (FGF2). Human endothelial cells cultured on Matrigel
substrates formed more numerous and longer tube-like structures
when supplemented with pAdv ECM bioscaffolds, and FGF2 mediated
this matrix signaling. ECM bioscaffolds derived from pAdv promoted
FGF2-dependent in vivo angiogenesis in the chick chorioallantoic
membrane model. Using an angiogenesis-focused protein array, we
detected 55 angiogenesis-related proteins, including FGF2 in hAdv,
pAdv and pSIS ECMs. Interestingly, 19 of these factors were less
abundant in ECMs bioscaffolds derived from aneurysmal specimens of
human aorta when compared with non-aneurysmal (normal) specimens.
This study reveals that Adv ECM hydrogels recapitulate matrix fiber
microarchitecture of native adventitia, and retain
angiogenesis-related factors and bioactive properties such as FGF2
signaling capable of influencing processes important for
angiogenesis. This work supports the use of Adv ECM bioscaffolds
for both discovery biology and potential translation towards
microvascular regeneration in clinical applications.
[0094] The potential for ECM bioscaffolds to invoke angiogenesis is
of particular importance for regenerative medicine applications.
Although the vasculogenic and angiogenic mechanisms of ECM
bioscaffolds are not fully understood, gradual release of growth
factors during ECM degradation is a likely mechanism of action.
Since immobilized growth factors secreted by the resident cells
fortify ECM, vascular ECM is a viable candidate biomaterial for
invoking vasculogenesis and angiogenesis. The adventitia of blood
vessels is a perivascular microenvironment that is heterogeneous in
both form and function. Not only does the adventitia provide the
majority of biomechanical strength to the vessel by nature of the
woven network of fibrous proteins of the ECM, but it also serves as
a progenitor cell niche. Furthermore, the diversity of cell
composition in the vascular adventitia renders this ECM
microenvironment a prime candidate for a multitude of desirable
bioactive effects on blood vessel cell populations. Understanding
the role of the adventitial ECM in vascular physiology will provide
insight into cardiovascular disease particularly by exploring ECM
bioscaffolds derived from human adventitia. Porcine adventitial ECM
(pAdv) bioscaffolds, with their greater availability, can be
utilized to harness their intrinsic bioactivity to develop
potentially regenerative therapeutics.
[0095] This study tested the hypothesis that perivascular ECM
contains bioactive signals that influence cells of blood vessel
lineages. The composition and gelation kinetics of ECM hydrogel
biomaterials formulated from human and porcine decellularized
aortic adventitia was characterized, and the signaling activity of
porcine ECM bioscaffolds in processes related to angiogenesis was
evaluated using primary adventitia-derived human endothelial cell
culture models, tube-forming in vitro assays, and an in vivo
angiogenesis model. Porcine small intestinal submucosa (pSIS) was
chosen as a control ECM due to its prior thorough characterization
and current utilization as a clinically-relevant bioscaffold. The
findings below reveal several biomimetic features of perivascular
ECM that may render these natural biomaterials useful for discovery
biology and show promise for regenerative medicine
applications.
Materials and Methods
[0096] Tissue Collection.
[0097] Human ascending thoracic aorta specimens (n=40 patients)
were collected during ascending aortic replacement operations or
heart transplants with informed patient consent and approval of the
institutional review board or from organ donors via the Center for
Organ Recovery and Education. Acquisition of all human specimens
was in accordance with the Helsinki Declaration of 1975, as revised
in 1983. Following excision, tissue specimens were placed in saline
on ice and transported to the laboratory. Specimens were collected
from 22 males and 18 females ranging in age from 17 to 82 years.
Porcine ascending aortic specimens were obtained from a commercial
source (Tissue Source, Lafayette, Ind.) and shipped on wet ice.
Porcine SIS specimens were obtained from a local abattoir (Thoma
Meat Market, Saxonburg, Pa.) and prepared as previously described.
Upon acquisition in the laboratory, all specimens were promptly
stored at -80.degree. C. until use.
[0098] Decellularization of Aortic Adventitia.
[0099] Adventitial ECM bioscaffolds were prepared from
decellularized aortic tissue specimens from 39 patients and two
pigs. The adventitial layer was delaminated from the media and
decellularized using a previously established method (Reing J E, et
al. The effects of processing methods upon mechanical and biologic
properties of porcine dermal extracellular matrix scaffolds.
Biomaterials. 2010; 31:8626-33). Briefly, the adventitial specimens
were incubated in a solution of 8 mM CHAPS (3-[(3-cholamidopropyl)
dimethylammonio]-1-propanesulfonate. Thermo Fisher Scientific,
Waltham, Mass.), 1M NaCl (Thermo Fisher Scientific), and 25 mM EDTA
(ethylenediaminetetracetic acid, Thermo Fisher Scientific) for 24
hr at 37.degree. C., followed by washing in Ix PBS (phosphate
buffered saline, Thermo Fisher Scientific) then in deionized water
(dH.sub.2O). The tissue was then placed on a shaker for 1 hour in a
solution containing 0.1% trypsin (Amresco, LLC, Solon, Oh.) and
0.04% EDTA, rinsed in dH.sub.2O, then shaken in a solution of 0.5%
SDS (sodium dodecyl sulfate, Thermo Fisher Scientific), 1M NaCl,
and 25 mM EDTA for 24 hr, followed by washing in 1.times.PBS and
dH.sub.2O. The tissue was then placed on a shaker in a solution of
0.1% peracetic acid (Rochester Midland Corporation, Rochester,
N.Y.) and 4% ethanol, followed by rinsing with ix PBS and dH.sub.2O
before freezing overnight at -80.degree. C. and lyophilizing.
Decellularized aortic adventitia from human and porcine aorta (here
on referred to as hAdv and pAdv ECM bioscaffolds) was lyophilized
and finely ground to produce an ECM bioscaffold powder for further
enzymatic digestion. SIS ECM bioscaffold was prepared previously as
described elsewhere (Badylak S F. et al. Small Intestinal Submucosa
as a Large Diameter Vascular Graft in the Dog. Journal of Surgical
Research. 1989; 47:74-80. Powdering and gelation of SIS utilized
the same procedures described in this report.
[0100] Qualitative and Quantitative Assessment of DNA Content.
[0101] Remnant DNA content was quantified from 25 mg of powdered
Adv ECM bioscaffolds from porcine (2 pigs, pooled) and human aorta
(4 patient specimens, pooled) using the QIAamp DNA Mini Kit
(QiAgen, Germantown, Md.) according to the manufacturer's
instructions. Final elution volume was 50 .mu.L Buffer AE. Qubit
2.0 (Thermo Fisher Scientific) was utilized to quantify the
concentration of dsDNA in each extract. DNA extracts front 1.2 mg
dry tissue weight of powdered ECM bioscaffolds and extracts from
1.2 mg wet tissue weight from native aorta were electrophoresed on
a 1% agarose (Thermo Fisher Scientific) gel containing 0.003% (v/v)
ethidium bromide (Sigma Life Science, St. Louis, Mo.) and
visualized under UV light on a Chemidoc XRS Bioimaging Station
(Bio-Rad, Hercules, Calif.).
[0102] Digestion of Powdered ECM Bioscaffolds.
[0103] Adv and pSIS ECM bioscaffold powders were digested at a
concentration of 20 mg/mL by stirring at 1600 RPM at room
temperature for 24 hr in a 0.01 N hydrochloric acid solution (pH 2,
Thermo Fisher Scientific) containing 1 mg/mL pepsin from porcine
gastric mucosa (.about.2000-2300 U/mg, Sigma). After 24 hr, the ECM
digests were either immediately used for gelation kinetics assays
or stored at -20.degree. C. for future use.
[0104] Detection of Collagen and Elastin Content.
[0105] Pepsin-soluble collagen was extracted from native adventitia
and from adventitia-derived ECM bioscaffold powder using 0.1 mg/mL
pepsin in 0.5M acetic acid overnight at 4.degree. C. After
isolation and concentration steps, the amount of pepsin-soluble
collagen was determined in each sample as previously described
(Phillippi J A, et al. Mechanism of aortic medial matrix remodeling
is distinct in patients with bicuspid aortic valve. J Thorac
Cardiovasc Surg. 2014; 147:1056-64) [38] using the Sircol Soluble
Collagen assay (Biocolor Ltd, UK), according to the manufacturer's
instructions. The amount of pepsin-soluble collagen determined in
each extract was normalized to weight of wet tissue or weight of
Adv ECM bioscaffold powder.
[0106] The amount of a-elastin was determined as described before
(Phillippi J A, et al. J Thorac Cardiovasc Surg. 2014; 147:1056-64)
using the Fastin Elastin assay (Biocolor), according to the
manufacturer's protocol. Insoluble elastin was converted to water
soluble a-elastin by subjecting native adventitia and Adv ECM
bioscaffold powder to three successive elastin extractions of one
hour each, in 0.25M oxalic acid at 100.degree. C. The amount of
.alpha.-elastin determined in each extract was normalized to weight
of wet tissue or weight of Adv ECM powder.
[0107] Formation of ECM Bioscaffold Hydrogels.
[0108] Hydrogels were formulated from ECM bioscaffold digests
according to an established method (Freytes D O, et al. Preparation
and rheological characterization of a gel form of the porcine
urinary bladder matrix. Biomaterials. 2008; 29:1630-7) and with all
preparations performed on ice. Briefly, the digest was diluted to
the desired final concentration and neutralized to a pH of
7.4.+-.0.2 in a solution of 10.times.PBS and 0.1 N NaOH (sodium
hydroxide, Thermo Fisher Scientific).
[0109] Hydrogel Gelation Kinetics.
[0110] Turbidimetric hydrogel gelation kinetics were determined for
porcine and human Adv ECM bioscaffold-derived hydrogels (4-16
mg/mL) as described previously (Freytes IX), et al. 2008;
29:1630-7). Optical density readings from 100 .mu.L aliquots of
neutralized ECM digest were obtained in triplicate every 2 minutes
at 405 nm for up to 2 hr using a spectrophotometer (TECAN,
Germany). Normalized absorbance (NA) was determined by the
following equation:
NA = A - A 0 A max - A 0 ##EQU00001##
where `A` represents the absorbance reading at a particular time
point, `A.sub.0` represents the initial absorbance and `Amax`
represents the maximum absorbance. Additional metrics of ECM
gelation determined include: the time required for 50% gelation,
defined as `t.sub.1/2`; the lag phase `t.sub.lag`, determined via
extrapolation of the linear portion of the normalized absorbance
curve; and the gelation speed `S`, calculated as the maximum slope
of the growth region for the normalized absorbance curve.
[0111] Morphological Ultrastructure Characterization of
Hydrogels.
[0112] hAdv, pAdv, and pSIS ECM bioscaffold hydrogels were prepared
at 8 mg/mL on 12 mm round cover glass (Thermo Fisher Scientific)
and fixed in 2.5% glutaraldehyde (Electron Microscopy Sciences,
Hatfield, Pa.) for 1 hour. Fixed hydrogels were rinsed three times
for 15 minutes in 1.times.PBS, treated in osmium tetroxide for 1
hour, and further rinsed three times for 15 minutes in 1.times.PBS
before dehydration in graded ethanol series for 15 minutes each
(30%, 50%, 70%. 90%, 100%). Dehydrated specimens were then critical
point dried with supercritical CO.sub.2 (Leica Biosystems, Buffalo
Grove, Ill.), allowing 15 minutes for processed hydrogels to soak
before each purge cycle. Following critical point drying, samples
were sputter coated with gold/palladium (Cressington Scientific
Instruments, Watford, England) at a thickness of 4.6 nm. The
surface morphology of hAdv, pAdv and pSIS ECM hydrogels was then
examined using a JSM 6335F scanning electron microscope (Jeol USA,
Inc., Peabody, Mass.) at 5,000.times. and 10,000.times. total
magnification and compared with intact specimens of decellularized
native human adventitia.
[0113] Isolation and Culture of Primary Adventitia-Derived Human
Endothelial Cells.
[0114] Primary endothelial cells were isolated from the adventitia
of a human specimen of thoracic aorta from a healthy donor. Upon
specimen acquisition in the lab within 1-2 hr of harvest, the
adventitia was immediately stripped away from the medial layer and
rinsed twice in ice-cold IX PBS with 1% (v/v)
penicillin/streptomycin and 1% (v/v) Fungizone (Invitrogen). Tissue
was then finely minced using safety scalpels and rinsed in
1.times.PBS. The tissue and PBS were placed in a 70 .mu.m molecular
sieve. The pass-through was collected and held at 37.degree. C.
while remaining tissue was digested in DMEM (Life Technologies)
containing 0.4% (w/v) collagenase type IV (Worthington Biochemical
Corporation, Lakewood, N.J.) and 350 KU/mL DNase I (Sigma) for 30
min at 37.degree. C. with gentle agitation. The digestion medium
and tissue was passed through a 70 .mu.m sieve and tissue was
returned to fresh digestion medium for another 30 min at 37.degree.
C. with gentle agitation. Following a final straining through a 70
.mu.m sieve and wash with 1.times.PBS, all filtrates were pooled
and centrifuged at 400 g for 10 min at 4.degree. C. Cells were
plated in 75 cm2 culture flasks in endothelial growth medium (EGM,
Cell Applications, San Diego, Calif.). Gentamycin (250 .mu.g/mL,
Thermo Fisher Scientific) was added for 24-48 hr. Cells were
maintained in a humidified incubation chamber at 37.degree. C. and
5% CO.sub.2 and expanded for 1-2 passages. Primary endothelial
cells were isolated from parent culture using fluorescence
activated cell sorting (FACS).
[0115] For FACS-based isolation of endothelial cells, expanded
adventitial cells were pelleted (.about.1-4.times.106 cells),
incubated in 1 .mu.L neat mouse serum (Sigma) on ice, protected
from light, and labeled with the following fluorochrome-conjugated
monoclonal mouse anti-human antibodies (2 .mu.L per antibody):
CD31-PE-Cy7 (Biolegend, San Diego, Calif., #303117), CD45-APC-Cy7
(BD Biosciences, San Jose, Calif., #348805), and CD34-ECD
(#BD2709U), and CD56-PE-Cy5 (IM2654, both from Beckman Coulter,
Indianapolis, Ind.). DAPI (200 ng/mL) was added to unfixed and
unpermeabilized cell suspensions just prior to sorting to
discriminate live from dead/apoptotic cells. Cells were sorted
using three of a five-laser MoFlo Astrios high speed cell sorter
(Beckman Coulter, University of Pittsburgh Cancer Institute Flow
Cytometry Core Facility) enclosed in a Class II biosafety cabinet.
Cells were sorted as previously described (Zimmerlin L, et al.
Stromal vascular progenitors in adult human adipose tissue.
Cytometry A. 2010; 77:22-30) on the basis of a mature endothelial
surface proteome of (CD56-/CD45-/CD34-/CD31+) into 6-well plates
containing EGM with gentamicin, expanded for 1-2 passages with
media replenishment every second day until cryopreservation.
[0116] Endothelial Cell Branching Assay.
[0117] Cell culture substrates were prepared by coating the surface
of wells in a 48-well culture plate with growth factor-reduced
(GFR) Matrigel (Corning) prepared in the presence or absence of
freshly-digested pAdv or pSIS ECM bioscaffold (250 .mu.g/mL).
Gelation was allowed to occur in a humidified 37.degree. C.
incubator for 1 hr. Primary human adventitia-derived endothelial
cells were seeded in triplicate on gel-based substrates at a
density of 1.5.times.10.sup.4 cells/cm.sup.2 in EOM. Digestion
buffer (1 mg/ml pepsin in 0.1N HCl) and DMSO only controls were
performed in adjacent wells. Where indicated, cells were treated
with 100 nM PD173074. To assess endothelial cell branching
formation of tube-like structures, large frame images were captured
at 7 hr post-cell seeding using a Nikon Eclipse TE2000-E microscope
equipped with an imaging array CoolSNAP ES2 monochrome camera and
NIS Elements Software (Nikon inc., Melville. N.Y.). Total number
and length of tube-like structures were quantified using NIS
Elements Software.
[0118] Chick Chorioallantoic Membrane (CAM) Model of In Vivo
Angiogenesis.
[0119] The CAM assay was modified from our established protocols
(Smith J D, et al. The use of quantum dots for analysis of chick
CAM vasculature. Microvasc Res. 2007; 73:75-83 and Smith J D, et
al. Improved growth factor directed vascularization into fibrin
constructs through inclusion of additional extracellular molecules.
Microvasc Res. 2007; 73:84-94). White Leghorn eggs were purchased
from a local farm and incubated at 37.degree. C. and 70% humidity
(G.Q.F. Manufacturing Co., Savannah, Ga.). On day 3 of incubation,
eggs were cracked into sterile petri dishes and incubated for 10
days. Fibrin scaffolds to be placed on the chicken chorioallantoic
membrane (CAM) were prepared similar to previously described
methods (Smith J D, et al. Improved growth factor directed
vascularization into fibrin constructs through inclusion of
additional extracellular molecules. Microvasc Res. 2007; 73:84-94;
Smith J D, et al. The use of quantum dots for analysis of chick CAM
vasculature. Microvasc Res. 2007; 73:75-83; and Jadlowiec J, et al.
Endocrinology. 2005; 146:3765-72). Briefly, final concentrations of
5 mg/mL bovine fibrinogen, 1 U/mL aprotinin (both from Enzyme
Research Labs, South Bend, Ind.) were buffered in 1.times.PBS, pH
7.4. Addition of digestion buffer (1 mg/mL pepsin in 0.1N HCl) to
fibrin scaffolds served as a negative control for angiogenic
response. The final concentration of pAdv ECM bioscaffold in fibrin
gels was varied from 50 .mu.g/mL to 500 .mu.g/mL in the presence or
absence of the FGF2 inhibitor PD173074 (100 nM in DMSO) or vehicle
control (0.05% (v/v) DMSO). Scaffold components were mixed and
incubated at 37.degree. C. for 30 min. Human thrombin (Enzyme
Research laboratory, South Bend, Ind.) was added to 1 U/mL to
initiate fibrin polymerization and incubated at 37.degree. C. for
60 min in a 48-well plate (Corning, N.Y.). Fibrin scaffolds
supplemented with the test materials were placed on the CAM and
incubated at 37.degree. C. with 70% humidity.
[0120] After 72 hr on the CAM, bright field images of the scaffolds
and surrounding vasculature resulting from the angiogenic response
were captured using a 3MP color camera mounted on a
stereomicroscope (AmScope, Irvine, Calif.) at a 7.5.times.
magnification. Endothelial cells of the chick vasculature were
labelled by micro-injecting DyLight.RTM. 650-labeled tomato lectin
(Vector labs, Burlingame, Calif.) and incubated for 15 min prior to
excising the scaffold and the surrounding CAM. The harvested tissue
was fixed in 10% neutral-buffered formalin (Sigma, St. Louis, Mo.)
for 48 hr, washed in IX PBS thrice and cryoprotected for 72 hr in
30% sucrose solution before processing for histological evaluation.
The scaffolds were dissected in half embedded in Tissue-Tek OCT
(Sakura Finetek USA Inc., Torrance, Calif.) and 60 .mu.m thick
sections were cut using a Microm HM5000M cryostat microtome (Thermo
Fisher Scientific). The sections were stained with Hoechst 33342
solution (Thermo Fisher Scientific) and imaged using Zeiss LSM 880
confocal microscope using a 10.times. objective. Tile scanning was
performed and the images were stitched using ZEN black microscope
and imaging software (Carl Zeiss Microscopy, Thornwood, N.Y.).
[0121] Protein Array.
[0122] Decellularized human adventitia from normal (n=7 patients)
and aneurysmal (n=28 patients) aortic specimens, and porcine
adventitia and SIS were analyzed for the presence of
angiogenesis-related proteins using the Protein Profiler.TM. Array
Human Angiogenesis Kit (R&D Systems, Minneapolis, Minn.)
according to the manufacturer's instructions. Briefly, lyophilized
ECMs were resuspended in RIPA buffer containing protease inhibitors
and homogenized using a douncer. Total protein concentration was
assessed using a bicinchoninic acid assay (Thermo Scientific) and
300 .mu.g of total protein was used as input for the array.
Densitometry measurements were made from duplicate spots of each
protein using ImageJ software (National Institutes of Health,
USA).
[0123] Statistical Analysis.
[0124] All experiments were repeated at least two times. Pairwise
comparisons in quantitative measures were made between treatments
and controls using an unpaired two-tailed Student's T test.
Quantitative data provided in the results section represent the
mean.+-.standard deviation. A p value of less than 0.05 was
considered statistically significant.
Results
[0125] Adv Bioscaffold Characterization.
[0126] Adventitia stripped from porcine and human aortic media were
decellularized, lyophilized, and ground into a fine powder (FIG.
9(A)). pH-neutralized pepsin-digested ECM bioscaffolds formed
hydrogels at 37.degree. C. (FIG. 9(B)). Qualitative assessment of
DNA content using gel electrophoresis revealed lower DNA content in
hAdv and pAdv bioscaffolds when compared with native specimens
(FIG. 9(C)). Total DNA content was found to be <40 ng/mg tissue
and <350 ng/mg dry tissue weight for hAdv and pAdv bioscaffolds,
respectively and <80 ng/mg for pSIS bioscaffolds. These pAdv and
hAdv bioscaffolds also retained appreciable collagen and a-elastin
(Table 1).
TABLE-US-00001 TABLE 1 Pepsin-soluble collagen and .alpha.-elastin
content in native adventitia and adventitia-derived ECM digest from
porcine and human aorta. Collagen Elastin Species Specimen
(.mu.g/mg tissue) (.mu.g/mg tissue) Porcine Native 2.75 (0.54) 3.61
(0.96) ECM Bioscaffold 18.0 (3.10) 1.95 (0.21) Human Native 0.56
(0.08) 1.35 (0.04) ECM Bioscaffold 21.2 (0.56) 3.71 (0.66) Data are
shown as mean (standard deviation).
[0127] Adv Bioscaffold Hydrogels Exhibit Fiber-like
Microarchitecture Similar to Native Adventitia.
[0128] The matrix ultrastructure of decellularized human adventitia
was investigated before the grinding and lyophilization steps of
the ECM bioscaffold preparation (FIG. 10(A, B)). Observation of
these specimens via scanning electron micrographs revealed an
acellular fibrous microarchitecture (FIG. 10(A, B)). A similar
microarchitecture was also observed in hydrogels produced from
digested hAdv (FIG. 10(C, D)) and pAdv (FIG. 10(E, F))
bioscaffolds, which exhibited a thinner and straighter morphology.
In comparison, hydrogels produced from digested pSIS bioscaffolds
displayed thicker, more undulated fibers, with additional globular
ECM apparently adhered to the fibers (FIG. 9G, H). The native-like
fibrous matrix microarchitecture of adventitia was recapitulated
following the decellularization, lyophilization, grinding,
digesting, and gelation processes utilized to produce ECM
bioscaffold hydrogels.
[0129] Gelation Kinetics for ECM Bioscaffold Hydrogels.
[0130] Optical density of ECM hydrogels over time revealed a
logarithmic curve during the gelation period at 37.degree. C. As
expected, increased optical density of the hydrogel was observed
for higher concentrations of pAdv ECM bioscaffold (FIG. 11(A)).
Ninety percent gelation occurred within 60 minutes and peak
gelation was reached within 90 minutes (FIG. 11(A)). A plot of the
normalized absorbance of pAdv, hAdv and pSIS ECM bioscaffolds
during gelation revealed similar rates of gelation among all
biomaterials tested (FIG. 11(B)). The speed (S), t.sub.lag, and
t.sub.1/2 of gelation as calculated from optical density readings
of ECM hydrogel formulations were similar at the 8 mg/mL
concentration for pSIS and pAdv groups (Table 2).
TABLE-US-00002 TABLE 2 Turbidimetric analysis of porcine
bioscaffold gelation kinetics. Representative calculations from one
of three independent batches of pepsin-digested bioscaffolds are
displayed. Density Material (mg/mL) S (OD/min) t.sub.1/2 (min)
t.sub.lag (min) SIS 8 0.04 (0.002) 29.3 (2.31) 17.59 (2.17)
Adventitia 4 0.02 (0.001) 30.7 (1.15) 1.96 (1.26) 8 0.03 (0.005)
32.0 (3.46) 9.76 (8.09) 16 0.03 (0.002) 34.0 (2.00) 14.16 (3.73)
Data are shown as mean (standard deviation). S, t.sub.1/2 and tlag
indicate gelation speed, time required for 50% gelation, and lag
phase respectively. O.D. = optical density.
[0131] Mitogenic Activity of Adv Bioscaffolds is FGF2-Mediated.
[0132] Primary human endothelial cells isolated from the aortic
adventitia exhibited increased cell proliferation with treatment of
pAdv ECM bioscaffold when compared to cells in their basal growth
medium (46.1.+-.2.5 vs. 0.0.+-.7.5%, p=0.0005) (FIG. 12). Treatment
of endothelial cells with pSIS ECM bioscaffolds increased cell
number when compared with control cells (34.0.+-.5.8 vs.
0.0.+-.7.5%, p=0.0005). pAdv ECM bioscaffold was found to be a more
potent mitogen when compared with an equivalent dose of pSIS ECM
bioscaffold (46.1.+-.2.5 vs. 34.0.+-.5.8%, p=0.018). Furthermore,
the effect of both ECMs was in part mediated by FGF2 since
inhibition of the FGF2 signaling pathway with PD173074 prevented
increases in cell number by pAdv ECM bioscaffold (25.9.+-.4.6 vs.
46.1.+-.2.5%, p=0.001) and pSIS ECM bioscaffold (18.7.+-.10.4 vs.
34.0.+-.5.8%, p=0.05). Elevated cell proliferation persisted even
in the presence of FGF2 inhibitor for both pAdv ECM bioscaffold
(25.9.+-.4.6 vs. 0.0.+-.7.5%, p=0.002) and pSIS ECM bioscaffold
(18.7.+-.10.4 vs. 0.0.+-.7.5%, p=0.03).
[0133] Adv Bioscaffolds Promote Tube-Like Structures In Vitro Via
FGF2.
[0134] There was minimal formation of tube-like structures by human
adventitia-derived endothelial cells on GFR-Matrigel substrates
alone (FIG. 13(A)) or substrates supplemented with pepsin HCl (FIG.
13(B)). Addition of pAdv ECM (FIG. 13(C)) and pSIS ECM (FIG. 13(D))
bioscaffolds to GFR-Matrigel substrates enhanced formation of
tube-like structures by endothelial cells when compared with cells
cultured on Matrigel alone (FIG. 13(A)) and substrates supplemented
with pepsin HCl digestion buffer alone (FIG. 13(B)). Addition of
the FGF2 inhibitor PD173074 did not affect tube-like formation on
Matrigel alone (FIG. 13(E)) or pepsin HCl-supplemented substrates
(FIG. 13(F)). Conversely, PD173074 decreased the tube-like
formation on pAdv ECM bioscaffold (FIG. 13(G)) and pSIS ECM
bioscaffold-supplemented substrates (FIG. 13(H)) when compared with
cells cultured on ECM bioscaffold-supplemented substrates in the
absence of FGF2 inhibitor (FIG. 13(C, D), respectively).
[0135] Quantification of the number (FIG. 13B) and total length
(FIG. 13C) of tube-like structures was consistent with our
qualitative observations and all values for treated cells were
compared with pepsin-HCl controls. We noted minimal endothelial
cell branching on Matrigel alone in the presence of DMSO or
PD173074 added to the culture medium. We observed an increase in
both the number and total length of tube-like structures on pAdv
ECM bioscaffold containing substrates when compared with pepsin-HCl
controls (151.7.+-.33.01 vs 54.7.+-.23.80 tubes, respectively,
p=0.017 and 27.8.+-.4.34 vs 9.5.+-.4.15 mm, respectively, p=0.006).
The presence of FGF2 inhibitor decreased the number and length of
tube-like structures when compared with the absence of inhibitor
for pAdv ECM bioscaffold (67.0.+-.39.89 vs 151.7.+-.33.01 tubes,
p=0.049 and 10.4.+-.6.20 vs 27.8.+-.4.34 mm, p=0.020). A similar
trend was noted for cells cultured on pSIS ECM-supplemented
substrates when compared with pepsin-HCl controls, an observation
which did not reach statistical significance (110.7.+-.36.95 vs
54.7.+-.23.80 tubes, respectively, p=0.104 and 17.9.+-.6.23 vs
9.5.+-.4.15 mm, respectively, p=0.135). The effect of FGF2
inhibition on tube-like formation on pSIS ECM-supplemented
substrates was similar to that of pAdv ECM for both tube number and
total tube length when compared with pepsin-HCl control but did not
reach 95% confidence (44.0.+-.18.08 vs 110.7 f 36.95 tubes,
respectively, p=0.069 and 6.7.+-.2.42 vs 17.9.+-.6.23 mm,
respectively, p=0.075).
[0136] In Vivo Angiogenic Activity of pAdv Bioscaffolds.
[0137] To evaluate the in vivo angiogenic potential of pAdv ECM
bioscaffold, we employed the chick CAM model for angiogenesis.
Qualitative inspection of pSIS ECM bioscaffold and pAdv ECM
bioscaffold-loaded fibrin scaffolds after 72 hr revealed
approximately the same level of angiogenic activity evidenced by
the "spoke-wheel" pattern of chick vasculature around the perimeter
of the scaffolds (FIG. 14A). Digestion buffer-loaded scaffolds did
not elicit any angiogenic response after 72 hr. Vascular invasion
into the scaffold occurred in a dose dependent manner with
increasing pAdv ECM bioscaffold concentrations up to 250 .mu.g/mL
(FIG. 14B, arrowheads). Although 50-500 .mu.g/mL pAdv ECM
bioscaffold all resulted in a spoke-wheel pattern around the
scaffold (FIG. 14A and FIG. 17), histological examination revealed
abrogated a vascular invasion front at the highest dose of pAdv ECM
(500 .mu.g/mL) (FIG. 14B). Addition of the FGF2 inhibitor PD173074
completely inhibited pAdv ECM bioscaffold (250 .mu.g/mL)-induced
angiogenesis and inclusion of the drug vehicle DMSO alone had no
effect on prom-angiogenic effects of pAdv ECM bioscaffold (FIG.
14C). We noted chemoattraction of lectin-negative cells invading
pSIS and pAdv ECM-loaded scaffolds (FIG. 14B, asterix) ahead of a
vascular front of migrating lectin-positive cells (FIG. 14B,
arrowheads). Representative higher magnification images of this
phenomenon for pAdv ECM-loaded scaffolds are displayed in FIG. 14D.
We observed an avascular zone of lectin-negative cells within the
pAdv ECM-loaded (250 .mu.g/mL) scaffold (FIG. 14D(i). asterix),
preceding invasion of migrating lectin-positive cells into the
scaffold (FIG. 14D(i), arrowhead). At higher concentrations of pAdv
ECM (500 .mu.g/mL), lectin-negative cells invaded the scaffold
whereas lectin-positive cells abutted and did not traverse the
scaffold/CAM interface (FIG. 14D(ii)).
[0138] Detection of Angiogenesis-Related Proteins in ECM
Bioscaffolds.
[0139] We detected the presence of all 55 proteins on an
angiogenesis-related commercial protein array in specimens of pAdv
and pSIS ECM bioscaffolds as well as hAdv bioscaffolds isolated
from normal and aneurysmal patients (FIG. 15). A complete list of
all array proteins which were detected and densitometry values are
displayed in FIG. 16. Qualitative inspection of array blots
revealed that FGF2 was detected in all ECM bioscaffolds (FIG. 15,
B19, B20). FGF1 and FGF2 (FIG. 15, B17, B18, B19, B20,
respectively) were more abundant in pSIS ECM bioscaffold when
compared with pAdv ECM bioscaffold (122.0.+-.4.43 vs 43.3.+-.0.7
pixel density (arbitrary units, p=0.022 and 100.2.+-.0.56 vs
43.5.+-.0.46 pixel density, respectively). Eight other
angiogenesis-related factors were more abundant in pSIS ECM than in
pAdv ECM bioscaffolds (FIG. 16). Interestingly, 19 proteins,
including FGF2, were found to be in lower levels in hAdv ECM
bioscaffold prepared from aneurysmal human aorta (>42 mm in
maximal orthogonal diameter) when compared with specimens of
non-aneurysmal aorta (<34 mm) (FIG. 16). Of note, thrombospondin
1 (TSP1) was approximately 3 times more abundant than the average
amount of all other proteins (60.0.+-.1.91 vs. 19.9.+-.1.34). None
of the detected angiogenesis-related factors were found to be
elevated in aneurysmal specimens when compared with normal
specimens.
[0140] In this study, we prepared a new ECM bioscaffold-based
hydrogel biomaterial from a perivascular microenvironment using
decellularized human and porcine aortic adventitial specimens. We
characterized these ECM bioscaffolds for their matrix protein
composition, microarchitecture and signaling activities on primary
human endothelial cells in vitro and in an in vivo model of
angiogenesis.
[0141] We demonstrated that ECM hydrogels self-assembled from
pepsin-digested decellularized adventitial tissue under
physiological conditions of pH, ionic strength and temperature to
resemble native adventitial ECM architecture. Hydrogels derived
from hAdv and pAdv ECM bioscaffolds recapitulated fibrous matrix
microarchitecture in striking similarity to that of native human
adventitia. These Adv ECM hydrogels exhibited a fiber morphology
that appeared to be straighter and less undulated than fibers of
hydrogels derived from pSIS ECM bioscaffold. The noted differences
in matrix fiber ultrastructure of these hydrogels are likely
dependent on the tissue-specific protein milieu which is
concordantly dictated by the unique biomechanical demands of that
tissue. For example, the aorta is a resilient, highly elastic
tissue that endures continuous cyclic loading without overt
dilatation or rupture in the absence of aneurysmal disease.
Contrarily, the intestine is more porous to facilitate nutrient
absorption, which may explain the observed decreased fiber density
and undulated fiber morphology following ECM bioscaffold gelation.
While further testing will ultimately determine the biomechanical
properties of adventitia-derived ECM hydrogels, the collagen- and
elastin-containing ECM bioscaffold hydrogels exhibited
micro-architectural mimicry of the native adventitia following
gelation. Analysis of the gelation kinetics of Adv ECM bioscaffold
hydrogels revealed a gelation rate profile similar to that of other
tissue sources such as pSIS for similar concentrations. The
observed similarity in gelation kinetics among pSIS and Adv ECM
bioscaffold hydrogels was unexpected due to the assumed
compositional differences in proteins of SIS and adventitial
microenvironments. Since hydrogel formation involves interplay
among self-assembling matrix proteins such as collagens and the
process can be modulated by laminin, fibronectin, and
proteoglycans, the interpretation of gelation activities is
complex. The observed similarities between the pSIS and Adv ECM
gelation kinetics suggest that unique tissues, even when processed
by different decellularization procedures can be ultimately
reconciled through the process of ECM bioscaffold gelation, which
similarly converts these unique ECMs to a hydrogel form. ECM
hydrogels across unique tissue sources could potentially be further
tailored by modulating the concentration of ECM bioscaffold. We are
interested in understanding the specific protein components and
functionality of pAdv ECM hydrogels and the present work further
focused on the inherent bioactive properties of porcine ECMs and
their influence on the in vitro behavior of human
adventitia-derived endothelial cells and on in vivo
angiogenesis.
[0142] We evaluated the influence of endogenous FGF2 within
pepsin-digested porcine ECM bioscaffolds on activities key to
angiogenesis. pAdv and pSIS ECM bioscaffold-induced proliferation
of endothelial cells was FGF2 mediated. The mitogenic activity of
both the Adv and pSIS ECM bioscaffolds in the presence of FGF2
inhibitor remained elevated above untreated controls to indicate
FGF2-independent signaling by ECM bioscaffolds that directs cell
proliferation, consistent with findings in porcine urinary bladder
and dermis ECMs. FGF2 also mediated the ECM-induced network
formation of tube-like structures by human adventitia-derived
endothelial cells.
[0143] pAdv ECM bioscaffolds exhibited greater mitogenic potency
than pSIS ECM bioscaffold, despite the increased abundance of FGF1
and 2 in pSIS ECM bioscaffold relative to Adv ECM bioscaffold. Two
interpretations can be made from this observation. First, the
tissue-specific milieu of the adventitia is advantageous for
endothelial cells derived from this locale perhaps through
retention of other tissue-specific growth factor dependent and
independent mitogenic signals. In addition or alternatively to this
explanation, it is reasoned that bioactivity capabilities differ
between pSIS and pAdv ECM bioscaffold preparations. Furthermore, we
detected every protein probed by the array in all ECMs prepared in
this study and the human-specific nature of the array precludes us
from making direct comparisons of protein abundance in human versus
porcine ECMs. Importantly, the presence of growth factors in ECM
scaffolds, such as bioactive FGF2 might also contribute to
maintenance of resident progenitor cell niches in the adventitia.
The decreased abundance of several angiogenesis-related factors in
human aneurysm raises numerous questions related to disease
mechanisms and offers opportunities to engineer in vitro models of
human disease using perivascular ECM bioscaffolds and evaluate the
therapeutic potential of the xenogeneic ECM counterparts in
vivo.
[0144] Using the chick CAM in viva angiogenesis model, we
demonstrated the in vivo angiogenic potential of pAdv ECM. The
vascular invasion noted with increasing concentrations of pAdv ECM
bioscaffold could be attributed to the higher concentration of FGF2
and other angiogenic factors in the scaffolds. We speculate that
the invasion of migrating lectin-negative cells are macrophages
preceding lectin-positive endothelial cells during angiogenesis in
response to pAdv and pSIS ECM-loaded scaffolds. We explain the
interesting observation of inhibited vessel invasion at the highest
dose of 500 .mu.g/mL pAdv ECM bioscaffold in one of two ways.
Either the present anti-angiogenic factors such as TSP1 interfere
with pro-angiogenic signals or negative feedback mechanisms in the
CAM are engaged by high concentrations of pro-angiogenic factors.
The complete abrogation of pAdv ECM bioscaffold in vivo angiogenic
potential in the presence of FGF2 inhibitor strongly suggests that
FGF2 is a major proangiogenic signal and potent regenerative factor
in adventitial ECM. Although alternative matrix signaling such as
mechano-transduction and integrin-mediated signaling contribute to
increased cellular proliferation, a review of in vitro angiogenic
and vasculogenic models by Morin and Tranquillo affirms that the
majority of the reports stated a required addition of exogenous
growth factors in order to achieve angiogenesis and/or
vasculogenesis with combinations of endothelial cells and pericytes
when ECM bioscaffolds were not utilized (Morin K T, Tranquillo R T.
In vitro models of angiogenesis and vasculogenesis in fibrin gel.
Experimental Cell Research. 2013; 319:2409-17). Recently, the in
viva angiogenic potential of pSIS bioscaffold hydrogels was
associated with matrix degradation-dependent release of FGF2 and
VEGF (Wang W, et al. Preparation and characterization of
pro-angiogenic gel derived from small intestinal submucosa. Acta
Biomaterialia. 2016; 29:135-48). Likewise, Adv ECM
bioscaffold-derived hydrogels serve as a depot for signals such as
FGF2 that influence cell behaviors important for blood vessel
formation.
[0145] For clinical applications, a select few ECM
bioscaffold-derived hydrogels would ideally be developed to invoke
regeneration in most diseased organs. Additionally, tissue-specific
ECM hydrogels can serve as natural biologic scaffolds which could
be useful for discovery biology of disease mechanisms. Although ECM
hydrogels from a variety of tissue sources exhibited inherent
bioactivity, investigation of their impact on angiogenesis emerged
only recently. These studies provided evidence that ECM
bioscaffolds influence and interact with blood vessel cells. The
angiogenic potential of hybrid scaffolds has been better studied
using synthetic materials conjugated with unique combinations of
tissue-derived angiogenic growth factors and must be precisely
engineered for specific applications with engineered growth factor
content and release profiles. ECM bioscaffolds offer a distinct
advantage over synthetic constructs in their tissue-specific
mimicry through multi-factorial structural and signaling
capacities. Furthermore, hydrogels derived from ECM bioscaffolds
can be tailored for specific tissue regeneration applications
through choice of source tissue, density and method of delivery.
Our findings collectively demonstrate that Adv ECM bioscaffold
hydrogels are versatile biological scaffolds that are capable of
both microstructural and growth factor-dependent signaling mimicry
of the native adventitia microenvironment which together are
important for desirable effects on cellular function of blood
vessel lineages.
Conclusions
[0146] We reveal that perivascular tissue from the human and
porcine aortic adventitia can be decellularized to derive ECM
bioscaffolds and formulated into hydrogels that recapitulate native
matrix fiber microarchitecture. pAdv ECM bioscaffolds retained
bioactive signals that invoked FGF2-mediated human endothelial cell
proliferation, network formation of tube-like structures in vitro,
and angiogenesis in vivo. Several angiogenesis-related proteins,
including FGF2, are present within Adv ECM bioscaffolds and many
were less abundant in matrix prepared from specimens of human
aneurysm. These findings provide support for the use of Adv ECM
bioscaffolds in further study of vasculogenesis and angiogenesis in
normal physiology in the setting of cardiovascular disease, and
also provide novel therapeutic opportunities.
Example 7--In Vivo Assessment of Decellularized Porcine Aortic
Adventitia ECM
[0147] Methods:
[0148] The in vivo pro-angiogenic properties of porcine aortic
adventitia ECM were assessed in a pilot assay using an adaptation
of a previously established subcutaneous matrigel-plug mouse model
(Passaniti, A., et al. (1992). A simple, quantitative method for
assessing angiogenesis and antiangiogenic agents using
reconstituted basement membrane, heparin, and fibroblast growth
factor. Laboratory investigation; a journal of technical methods
and pathology, 67(4), 519-528). Briefly, 6-8 week old C57BL6J mice
(25-30 g) were anesthetized and four horizontal incisions (12 mm)
were made on the dorsal side to create subcutaneous pocket for
scaffold implantation. The scaffolds were prepared by casting 250
.mu.L of 10 mg/mL fibrin (with or without neutralized porcine
adventitia ECM bioscaffolds) in a standard 48 well plate. At 7 and
14 days post-implantation, Dylight.RTM. 650-tomato lectin was
injected via the tail vein to label the vasculature. Fifteen
minutes post injection, animals were sacrificed and the scaffold
along with the surrounding tissue was harvested and fixed in 10%
neutral buffered formalin for 48 hours. Half of each specimen was
allocated for analysis of hematoxylin and eosin (H&E) and
Masson's Trichrome stained paraffin embedded section. The other
half of each specimen were evaluated for lectin-labeled vasculature
in cryosections.
[0149] Results:
[0150] Preliminary results revealed increased pro-angiogenic
activity of pAdv ECM-loaded fibrin scaffolds when compared with
unloaded fibrin scaffolds (FIG. 18 (A)), consistent with our
observations of angiogenesis with pSIS and pAdv ECM scaffolds in
the CAM model described above. Qualitative microscopic inspection
of H&E-stained paraffin embedded sections revealed greater cell
infiltration (speculatively macrophages) of the scaffolds 14 days
after implantation with pSIS and pAdv ECM-loaded fibrin when
compared with unloaded fibrin alone or gels supplemented with
digestion buffer alone (FIG. 18(B)). Furthermore, the pAdv
ECM-loaded scaffold seemed to be more degraded with more
infiltrating cells than scaffolds loaded with SIS ECM.
[0151] The following clauses provide examples of various aspects of
the invention described herein. [0152] 1. A method of preparing an
extracellular matrix (ECM) material, comprising: [0153] a.
incubating vascular adventitial tissue in a zwitterionic detergent,
wherein the vascular adventitial tissue is optionally bovine,
ovine, or porcine; [0154] b. incubating the tissue in Trypsin-EDTA;
[0155] c. incubating the tissue with an anionic detergent; [0156]
d. disinfecting the tissue, optionally with peracetic acid,
producing a decellularized ECM material; [0157] e. lyophilizing the
decellularized ECM material; [0158] f. comminuting the
decellularized ECM material; [0159] g. partially or completely
solubilizing the decellularized ECM material with an acid protease
to produce solubilized ECM; and [0160] h. neutralizing the
solubilized ECM to produce an ECM pre-gel. [0161] 2. The method of
clause 1, wherein the adventitial tissue is aortic adventitia.
[0162] 3. The method of any one of clauses 1 or 2, further
comprising gelling the ECM pre-gel at a temperature at which the
ECM pre-gel gels to produce an ECM gel. [0163] 4. The method of any
one of clauses 1-3, wherein the decellularized ECM material is not
completely digested with the acid protease, producing an ECM
pre-gel that is able to gel at 37.degree. C. comprising undigested
decellularized ECM particles. [0164] 5. The method of any one of
clauses 1-4, further comprising including one or more washing steps
from prior to step e. [0165] 6. The method of clause 5, wherein the
one or more washing steps comprises washing the tissue or material
with phosphate-buffered saline, saline, and/or water. [0166] 7. The
method of any one of clauses 1-6, wherein the ECM material is
prepared without a dialysis step or a crosslinking step. [0167] 8.
The method of any one of clauses 1-7, wherein the zwitterionic
detergent is CHAPS. [0168] 9. The method of any one of clauses 1-8,
wherein the anionic detergent is SDS. [0169] 10. The method of any
one of clauses 1-9, wherein the acid protease is pepsin. [0170] 11.
The method of any one of clauses 1-10, wherein the decellularized
ECM material is solubilized with an acid protease in a solution
having a pH of from 1 to 4, from 1 to 2, or 2.0.+-.0.3. [0171] 12.
The method of any one of clauses 1-11, comprising dispersing the
ECM material in a natural or a synthetic polymer composition.
[0172] 13. The method of clause 12, wherein the natural or a
synthetic polymer composition is one or more of: a second ECM
material, fibrin, collagen, polyester (PE), polyurethane (PU),
poly(ester urethane) urea (PEUU), poly(ether ester methane) urea
(PEEUU), poly(ester carbonate urethane)urea PECUU), poly(carbonate
urethane)urea (PCUU) copolymer, polyolefin (polyalkene),
polycarbonate, polyanhydride, polyether, polyurea, polyurethane,
polyketone, and fluoropolymer. [0173] 14. The method of clause 12
or 13, wherein the ECM material is mixed with the natural or
synthetic polymer composition prior to or during gelation of the
ECM material. [0174] 15. The method of clause 12, wherein the
pre-gel is mixed with fibrin and fibrinogen and is gelled while the
fibrin is cross-linked with the fibrinogen. [0175] 16. An ECM
composition comprising devitalized, acid-protease-digested aortic
adventitial tissue, having a pH of from 6.8 to 7.8. [0176] 17. The
ECM composition of clause 16, wherein the composition is a gel and
as compared to acid-protease-digested porcine small intestine
submucosa, the gel comprises longer fibers and at least 50% lower
FGF-1 and/or FGF-2 content, and optionally has increased HB-EGF
(Heparin Binding EGF Like Growth Factor) content and/or lower
content of one or more of Angiopoietin 2; Endostatin; IGFBP1
(Insulin Like Growth Factor Binding Protein 1); PTX3 (Pentraxin 3);
Prolactin; Serpin B5; and/or TIMP4 (TIMP Metallopeptidase Inhibitor
4), and optionally has at least 50% lower FGF-1 and/or FGF-2
content, increased HB-EGF (Heparin Binding EGF Like Growth Factor)
content, and lower content of Angiopoietin 2; Endostatin; IGFBP1
(Insulin Like Growth Factor Binding Protein 1); PTX3 (Pentraxin 3);
Prolactin; Serpin B5; and TIMP4 (TIMP Metallopeptidase Inhibitor
4). [0177] 18. The composition of clause 16 or 17, wherein the
devitalized, acid-protease-digested aortic adventitial tissue is
not dialyzed or chemically crosslinked. [0178] 19. A method of
treating an aneurysm in a patient, comprising administering to a
surface of a blood vessel having an aneurysm, a devitalized,
acid-protease-digested vascular adventitial tissue, having a pH of
from 6.8 to 7.8, wherein the vascular adventitial tissue is
optionally aortic adventitial tissue. [0179] 20. The method of
clause 19, wherein the blood vessel is the aorta of the patient.
[0180] 21. The method of clause 19 or 20, wherein the devitalized,
acid-protease-digested vascular adventitial tissue is prepared by:
[0181] a. incubating vascular adventitial tissue, such as aortic
adventitial tissue, in a zwitterionic detergent, wherein the
vascular adventitial tissue is optionally bovine, ovine, or
porcine; [0182] b. incubating the tissue in Trypsin-EDTA; [0183] c.
incubating the tissue with an anionic detergent; [0184] d.
disinfecting the tissue, optionally with peracetic acid, producing
a decellularized ECM material; [0185] e. lyophilizing the
decellularized ECM material; [0186] f. comminuting the
decellularized ECM material; [0187] g. partially or completely
solubilizing the decellularized ECM material with an acid protease
to produce solubilized ECM; [0188] h. neutralizing the solubilized
ECM to produce an ECM pre-gel, and [0189] i. optionally, gelling
the ECM pre-gel at a temperature at which the ECM pre-gel gels to
produce an ECM gel. [0190] 22. A method of vascularizing or
re-vascularizing living tissue in a patient, comprising
administering to a surface of a tissue ex vivo, or in vivo, a
devitalized, acid-protease-digested vascular adventitial tissue,
having a pH of from 6.8 to 7.8, wherein the vascular adventitial
tissue is optionally aortic adventitial tissue. [0191] 23. The
method of clause 19, wherein the tissue is a living blood vessel.
[0192] 24. The method of clause 19, wherein the tissue is a wound
of a patient, optionally a skin wound, a diabetic ulcer, or a
diabetic foot ulcer, and the devitalized, acid-protease-digested
vascular adventitial tissue is administered to the wound. [0193]
25. The method of clause 19, wherein the tissue is living bone
tissue of a patient, optionally a damaged bone, or bone exhibiting
osteoporosis, and the devitalized, acid-protease-digested vascular
adventitial tissue is administered to the bone. [0194] 26. The
method of clause 19, wherein the tissue is myocardium and/or
vasculature thereof in a patient, optionally a wound in a patient's
myocardium or an infarct, and the devitalized,
acid-protease-digested vascular adventitial tissue is administered
to the patient's myocardium, and optionally to the wound or infarct
in the patient's myocardium. [0195] 27. The method of any one of
clauses 22-26, wherein the devitalized, acid-protease-digested
vascular adventitial tissue is prepared by: [0196] a. incubating
vascular adventitial tissue, such as aortic adventitial tissue, in
a zwitterionic detergent, wherein the vascular adventitial tissue
is optionally bovine, ovine, or porcine; [0197] b. incubating the
tissue in Trypsin-EDTA; [0198] c. incubating the tissue with an
anionic detergent; [0199] d. disinfecting the tissue, optionally
with peracetic acid, producing a decellularized ECM material;
[0200] e. lyophilizing the decellularized ECM material; [0201] f.
comminuting the decellularized ECM material; [0202] g. partially or
completely solubilizing the decellularized ECM material with an
acid protease to produce solubilized ECM; [0203] h. neutralizing
the solubilized ECM to produce an ECM pre-gel, and [0204] i.
optionally, gelling the ECM pre-gel at a temperature at which the
ECM pre-gel gels to produce an ECM gel.
[0205] Having described this invention, it will be understood to
those of ordinary skill in the art that the same can be performed
within a wide and equivalent range of conditions, formulations and
other parameters without affecting the scope of the invention or
any embodiment thereof.
* * * * *